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Chapter 1
General introduction
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This is a thesis about implementing pharmaceutical care, or more specifically, about 
strategies to support the implementation of pharmaceutical care in community 
pharmacies. In this introduction a short history and definitions of pharmaceutical care 
are provided as well as an overview of the literature which underpins the importance 
and potential benefits of pharmaceutical care. This introduction will then clarify the 
chosen targets for improvement in community pharmacies and the implementation 
strategies applied. Finally, the main research questions of this thesis and a short 
overview of the thesis are presented.
Pharmaceutical care, a short history and definitions
Until the 19th century, pharmacists were mainly involved in composing mixtures of 
medicinal herbs and later in manufacturing drugs, using active substances isolated from 
plants and herbs. In the second half of the 19th century it became possible to synthetise 
and manufacture medicines on an industrial scale and after World War II the repertory 
of drugs expanded enormously1. The need for the manufacturing skills of pharmacists 
and pharmacy technicians decreased as a consequence of these developments. In the 
1960s and 1970s social pharmacy and medication surveillance became part of the 
pharmaceutical curriculum in the Netherlands2. This catalyzed a move towards patient 
centered pharmaceutical care, although the communication was still one-way traffic. 
Only in the last decade of the 20th century, the importance of two-way communication 
with patients started to be acknowledged. In addition, the communication and 
collaboration with general practitioners (GPs) was enhanced, for instance by the 
development and implementation of pharmacotherapy audit meetings in the 1990s. In 
these meetings, pharmacists and GPs study pharmacotherapeutic subjects, e.g. new 
drugs, guidelines, and prescribing patterns2.
The concept of pharmaceutical care was explicitly introduced in the last quarter of the 
20th century in the USA. Several definitions of pharmaceutical care have been 
formulated3-5, of which the one by Hepler and Strand is the most widely used: “the 
responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient’s quality of life”. In this definition they included a social 
responsibility for the reduction of preventable drug-related morbidity and mortality, 
and emphasized the importance of an orientation towards patient outcomes. Three 
distinct functions should be performed in the process of pharmaceutical care6: 
initiating therapy, monitoring therapy and managing (correcting) therapy. Thus, in this 
view, pharmaceutical care requires a team approach of at least the physician, the 
patient and the pharmacist. With regard to the European situation, Van Mil and 
Tromp2;7 clearly described that different languages, different pharmacy systems and 
different healthcare systems influence the operationalization of pharmaceutical care in 
different countries. The extent to which the focus should be on the patient and on 
outcomes, and whether pharmacists are the preferred, or even the sole providers of
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pharmaceutical care, are subjects for debate internationally2. A common opinion in 
European practice seems to be that pharmaceutical care is individually oriented care 
around pharmaceuticals or drug therapy, and that the pharmacy profession claims a 
central role in providing this7.
The importance of pharmaceutical care
In recent years it has become clear that drug-related morbidity is a significant 
healthcare problem, and that a great proportion of it is preventable8. In the US, the 
Institute of Medicine wrote in its report To Err Is Human 2000.4: “Because of the 
immense variety and complexity of medications now available, it is impossible for 
nurses or doctors to keep up with all of the information required for safe medication 
use. The pharmacist has become an essential resource ... and thus access to his or her 
expertise must be possible at all times”9. Several systematic reviews have shown that 
pharmaceutical care can reduce drug related problems and that it can improve 
outcomes in many diseases, prescribing practice, patient satisfaction and resource use 
indeed10-14. Unfortunately, interventions that proved to be effective are not necessarily 
implemented widely in daily practice. Opportunities for improvement in clinical, 
service, and cost outcomes related to pharmaceutical care include, among others: 
adverse drug events; patient adherence to or concordance with therapy; attainment of 
target goals of blood pressure, glucose, and lipid levels; risk reduction for adverse 
cardiac events and osteoporotic-related fractures; patient satisfaction; risk of 
hospitalization or mortality; and cost of care15.
Targets for improvement
The framework for the research described in this thesis was developed in close 
consultation with “CZ Actief in gezondheid”, a not-for-profit health insurer and major 
funder of our research. It wanted to enhance the role for pharmacists to influence GPs’ 
prescribing, which would imply a major innovation in healthcare delivery. Its primary 
interest was to decrease overprescribing of specific drug classes and to reduce the 
avoidable associated costs. As pharmacists were remunerated at that time by a fee for 
each drug product dispensed, we recognized that a successful project could have a 
direct negative effect on the earnings of the participating pharmacies and we were 
concerned that this might represent a barrier to large-scale participation. Since it was 
becoming more and more clear that underprescribing also constituted a major issue in 
the quality of prescribing16, we proposed to offer a mix of interventions targeting both 
overprescribing and underprescribing.
We chose our specific research topics on the basis of the following criteria: (1) the 
quality of pharmacotherapy provided shows room for improvement; (2) it concerns 
overprescribing/overuse or underprescribing/underuse of specific drugs; (3) a 
pharmaceutical care service with proven effectiveness is available, but not widely
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implemented; (4) the expected size of the patient group eligible for the 
pharmaceutical care topic should be large enough to measure the effect of our 
intervention; (5) the patient group at which the service was targeted was not likely to 
receive much attention from other research groups or other projects aimed at 
improving prescribing practice. The topics we chose were:
- sending discontinuation letters to long-term benzodiazepine users17;
- improving statin prescribing for patients with established cardiovascular disease18;
- providing patient education at first and second dispensing of statins to these 
patients;
- the use of an electronic monitoring system to assess medication adherence in 
patients with hypertension despite the use of antihypertensive medication19.
These topics covered simple as well as more complex forms of pharmaceutical care.
Development of implementation strategies
Not only clinical research on drug treatments, but even most research on 
pharmaceutical care interventions consists of efficacy research. In this research the 
focus is on the effectiveness of interventions under highly controlled and optimized 
conditions. In these studies, it is often unclear from what population of pharmacies 
study participants have been recruited. Because pharmacies generally participate 
voluntarily, it is likely that active participants are mainly selected from the innovator 
or early adopter categories of pharmaceutical care20. In addition, much effort is done 
in these studies to enhance the participants’ adherence to the planned activities and to 
include patients. As a consequence, an important part of the implementation activities 
(to enhance treatment integrity) remains hidden and the generalizability of these 
studies to real practice is uncertain. In this thesis we aimed to assess the effectiveness 
of implementation of the pharmaceutical care services mentioned before in conditions 
that reflect usual practice rather than an optimized version of it.
An implementation strategy widely used in pharmacy practice consists of providing a 
written manual to pharmacists. However, for the implementation of new guidelines or 
innovations a comprehensive approach in which barriers and facilitators to change in a 
specific setting are targeted is generally needed21. We therefore developed a 
multifaceted implementation strategy tailored at pharmacists’ needs, following a 
model for stepwise developing and testing implementation interventions, described by 
Grol and Wensing22.
Study objectives and outline of this thesis
This thesis investigates the impact of an intensive implementation strategy directed at 
pharmacists on the implementation of four pharmaceutical care services in three 
different trials. The impact of the strategy on each of the services is described in a 
separate chapter. We also report on a study assessing the appropriateness of a marker
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used to identify patients with established cardiovascular disease that was used in our 
second trial. The research questions of the studies are:
1. How effective is an intensive programme to support community pharmacies in the 
implementation of the sending of discontinuation letters, compared to a usual - 
more passive - dissemination of pharmaceutical services? (Chapter 2)
2. (a) Which method serves best to identify all patients with atherothrombotic 
cardiovascular disease in Dutch primary care: morbidity records, antiplatelet 
prescribing records, or a combination of these? (Chapter 3)
(b) Does an intensive programme improve the implementation of appropriate 
prescribing of statins to eligible patients? (Chapter 4)
(c) Does an intensive implementation programme increase the frequency of patient 
education provided at first and second dispensing of statins in community 
pharmacies? (Chapter 5)
3. Does an intensive, multifaceted programme for pharmacists, tailored to a setting in 
which community pharmacists cooperate with general practitioners, improve the 
implementation of an electronic adherence support intervention more than sending 
an educational manual to pharmacists? (Chapter 6)
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Implementation of a discontinuation letter to reduce 
long-term benzodiazepine use—A cluster randomized trial
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Abstract
Rationale: Although it is recommended to restrict long-term use of benzodiazepines, 
and considerable attention has been paid to this, long-term use continues to be a 
problem. An informative discontinuation letter for patients has been shown to reduce 
long-term benzodiazepine use in general practice. However, little is known about its 
wide-scale implementation in primary care.
Objective: To determine the effectiveness of an intensive support programme for 
community pharmacies to send discontinuation letters to patients in cooperation with 
GPs.
Methods: In a cluster randomized trial, 43 control pharmacies received a written 
manual and 47 experimental pharmacies received an intensive support programme. 
Primary outcome measures were the percentage of GPs who reviewed and returned 
lists of eligible patients and the percentage of long-term users who were sent a 
discontinuation letter within 4 months.
Results: The outcomes did not differ for the experimental versus control groups: 38% 
and 30% (P=0.409) of the GPs, respectively, returned the patient lists; 14% and 10% 
(P=0.690) of all long-term users in the two groups, respectively, received the 
discontinuation letter within 4 months. Substantially more pharmacies in the 
experimental group than in the control group finally managed to send discontinuation 
letters (70% vs. 40%, P=0.069).
Conclusion: About one third of the pharmacies in the control group and two thirds of 
the pharmacies in the intervention group finally implemented the discontinuation 
letter. However, this difference was not apparent in the primary outcome measures. It 
seems crucial to involve GPs more effectively in implementation of the discontinuation 
letter.
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Introduction
It is generally recommended that the initial and continued prescription of 
benzodiazepines be restricted, and many efforts have been made to reduce their long­
term use. While these efforts have produced some improvement, prolonged use 
remains a problem1. Longterm benzodiazepine use is undesirable because effectiveness 
in the long run is outweighed by such risks as cognitive impairment, benzodiazepine 
dependence, hip fractures and traffic accidents2-10.
In several studies, an informative discontinuation letter from the general practitioner 
(GP) to patients has been shown to be an effective means to reduce long-term 
benzodiazepine use11-13. After having received a letter, about one fifth of long-term 
users have been found to have discontinued use at 6 months11,12. At long-term, one 
eighth of the long-term users were still free of benzodiazepine prescriptions11,13. The 
patient letter is effective, simple and inexpensive14. Nevertheless and despite the call 
for large-scale implementation15, the sending of letters to long-term users has not been 
incorporated into routine primary care.
While improved implementation in general practice is certainly a possibility, we 
considered an innovative alternative for wide-scale implementation of the 
discontinuation letter in primary care, namely the sending of the letter via community 
pharmacies. Since the introduction of the concept of pharmaceutical care in the 
1990s16, cognitive pharmaceutical services with a focus on potential and actual drug- 
related patient problems, have been incorporated into the daily practice of many 
community pharmacies in North America, Australia and Western Europe with notable 
differences within and between countries17-22. The focus of the present study was thus 
on the question of whether and how the sending of a discontinuation letter to long­
term users of benzodiazepines could be implemented as a component of the 
pharmaceutical care provided in Dutch community pharmacies. More specifically, the 
effectiveness of an intensive programme to support community pharmacies in the 
implementation of the sending of discontinuation letters was compared to a usual - 
more passive - pharmaceutical dissemination practice.
Methods
A cluster randomized trial was carried out between October 2005 and March 2006. The 
medical ethical committee in Arnhem-Nijmegen approved the study.
Participants
Ph ar m a c ies
Community pharmacies in the South of The Netherlands were invited to participate in 
the study during special regional meetings of pharmacists and via a mailing to all of the 
305 pharmacies in this region. Participation was voluntary but encouraged by one of the 
two major health insurance companies in this part of The Netherlands as those
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pharmacies which participated were exempted from having to submit their annual 
plans and reports of patient care activities. No additional financial incentive for 
participation in the project beyond standard reimbursement was provided. Those 
pharmacies which registered and had deposited all dispensing data for the past 12 
months with the Foundation for Pharmaceutical Statistics (SFK1) were included in the 
study.
G en er a l  pr a c t it io n er s
Pharmacists were instructed to introduce the project to those GPs from whom they 
regularly receive benzodiazepine prescriptions. This is largely those GPs who take part 
in the standard pharmacotherapy audit meetings (PTAMs) which are held an average of 
five or six times a year with the pharmacist to discuss pharmacotherapy topics, often 
on the basis of GP prescription data23. PTAM groups generally involve a pharmacist with 
a minimum of three GPs and a maximum of twelve persons24.
Pa t ien t s
In each participating pharmacy, long-term users of benzodiazepines were identified on 
the basis of prescription data from October 2004 through September 2005 included on 
the online SFK database. Long-term use of benzodiazepines was defined as the 
dispensing of at least four prescriptions for benzodiazepines (anatomical therapeutical 
codes (ATC) N05BA, N05CD or N05CF) for at least 91 dosage units (tablets or capsules) 
in total in the relevant 12-month period including prescriptions for at least 60 dosage 
units in the last 3 months of the 12-month period25.
The pharmacists next gave the rough list of long-term users of benzodiazepines to the 
collaborating GPs who were then asked to exclude those patients who were not eligible 
for inclusion in the intervention for any of the following reasons (see Gorgels et al.11):
(A) Medical reason: Currently being treated by specialist for mental illness; drug or 
alcohol dependence; psychotic episodes in medical history; epilepsy; terminal 
illness; or severe co-morbidity.
(B) Psychosocial reason: Insufficient mastery of the Dutch language or such individual 
reasons as psychosocial conditions, old age, or severe disability in the opinion of 
the GP.
(C) Administrative reason: Has moved or changed practices, among other things. 
Randomization
The participating pharmacists completed a baseline inventory, which also included a 
question on collaboration with other pharmacies participating in the present project. In 
order to avoid pharmacies in the control group benefiting from the experiences of the
1 The SFK gathers data directly from a panel of pharmacies which includes more than 1650 of the 1825
community pharmacies in The Netherlands. The panel pharmacies serve about 13.5 million people and 
dispense drugs or medical aids some 140 million times per year. http://www.sfk.nl/algemeen/ 
english.html.
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pharmacies in the experimental group (i.e., contamination of the research data by 
collaboration), we clustered the reported collaborations of pharmacies for purposes of 
randomization. The pharmacy clusters were then numbered according to the order of 
enrolment for the first pharmacy in each of the clusters. An independent statistician 
then generated an allocation sequence with a computerized random-number generator, 
consisting of random blocks of one control and one experimental group. The pharmacy 
clusters were then allocated to the experimental or control groups on the basis of the 
numbers which they had been assigned.
Interventions
D irected  a t  p h a r m a c ie s: ex per im en t a l  g r o u p
It was expected that a combination of educational materials, educational meetings and 
reminders would be more effective than the provision of educational materials alone26. 
For this reason, an intensive implementation programme was developed. The 
programme included an educational manual; an interactive educational meeting which 
was held at the start of the study and tailored to the individual needs of the 
pharmacists; and one or more telephone calls by a coach to remind the pharmacist to 
get started on the intervention and ask if they needed more help. The educational 
manual consisted of information about the project, step-by-step instructions for 
managing the project, schedules for the reduction of benzodiazepine use, an electronic 
example of the discontinuation letter encouraging patients to discontinue their 
benzodiazepine use, background information regarding long-term benzodiazepine use 
and publications on the effectiveness of sending such a letter to long-term users of 
benzodiazepines. The first phone call was made about four weeks after the pharmacists 
had planned to initiate the intervention. If desired after the first call, the pharmacists 
could schedule a second follow-up call.
The main barriers to implementation of the intervention were expected on the basis of 
the research literature27-33, outcomes of the baseline inventories and the extensive 
experience of two professional communication advisors with community pharmacies - 
to be the communication and cooperation between pharmacists and GPs. The 
interactive educational meeting with a duration of six hours was therefore specifically 
designed to address the cooperation with GPs. The pharmacists listed and discussed 
perceived barriers to and facilitators of cooperation with GPs; were informed about 
some essential aspects of communication with GPs; analyzed their individual strengths 
and weaknesses, which were then discussed with the entire group; practiced points for 
improvement; and made a plan for communication regarding the present intervention 
with the GPs.
The educational meetings were held at the end of September or the beginning of 
October 2005 with between seven and fifteen pharmacists included in a meeting. The 
first telephone call was made between November 2005 and January 2006 as the
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pharmacists had planned to start with the intervention between October and December 
of 2005.
D irected  a t  p h a r m a c ie s: c o n t r o l  g r o u p
The pharmacies in the control group received only the written educational manual in 
September 2005. No further implementation support was given.
D irected  a t  pat ien ts
In both the experimental and control groups, the pharmacists were expected to 
undertake a number of activities: identify long-term users of benzodiazepines and 
present the resulting list to cooperating GPs for exclusion of those long-term users who 
should not be sent a discontinuation letter for one reason or another. The 
benzodiazepine discontinuation letter, which recommends gradual reduction of the 
medication and stopping in the end, was signed by both the GP and the community 
pharmacist and supposed to be mailed to the relevant patients by each of the 
pharmacies in both the experimental and control groups. The letter used by Cormack et 
al.12 was adopted as a model for the discontinuation letter in the present study. 
Patients who wanted to stop but thought that they would not be able to do this on their 
own were also instructed in the letter to contact their pharmacist or - if the 
cooperating GP preferred this - their GP.
Measurements
The baseline characteristics of the pharmacies were assessed prior to random 
assignment to the control or experimental groups. To check whether the randomization 
procedure had indeed produced initially comparable groups of pharmacies, those 
characteristics indicated in previous research as possibly influencing the care-providing 
function of pharmacists were compared for the groups: a positive attitude on the part 
of the pharmacist with respect to care-providing function; good relationship with GPs; 
presence of technicians with a specialized care duty; involvement in the training of 
pharmacists; number of years in service of the managing pharmacist and frequent 
participation in pharmacotherapeutic postgraduate training programmes32. We also 
considered the number of pharmacists in the pharmacy; workload; sufficient personnel 
to accomplish standard tasks; encouragement of technicians to attend pharmaceutical 
care classes; certification of the pharmacy; participation in a pharmacy chain or 
franchise formula; cooperation with other pharmacies on pharmaceutical care projects; 
percentage of prescriptions from GPs received electronically; prior focus on long-term 
benzodiazepine use; frequency of participation in PTAM meetings; judged importance 
of PTAM; and participation in the present project because the pharmacist thought that 
the health insurance company required this.
The baseline characteristics of the patients extracted from the SFK database for the 
period between October 2004 and September 2005 were: age, gender and amount of 
benzodiazepine use 3 months prior to inclusion in the study in October 2005.
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The outcome benzodiazepine prescription information for the participating patients 
was extracted from the SFK database for the period between October 2005 and 
December 2006. Benzodiazepine use was calculated in terms of “defined daily doses” 
(DDDs) in diazepam equivalents using the WHO ATC/DDD Index 200525.
The success of the implementation and descriptive information regarding the 
implementation processes for both the control and experimental groups were measured 
at the end of the study using a written questionnaire, which the pharmacists were 
asked to complete and return. Those pharmacists who had not returned the 
questionnaire by July 2006 were called by a research assistant to obtain information on 
the implementation process and whether or not any discontinuation letters had been 
sent. Pharmacies from which no questionnaires were received and whose pharmacists 
were not reachable for telephone interview after several attempts were considered not 
to have started the intervention (these pharmacies were included in the data analyses 
by recording a value of zero for each step of the implementation process). The number 
of GPs regularly participating in the PTAMs according to the baseline inventory provided 
the denominator for calculation of the percentages of GPs for various measurements. 
Prescription changes were calculated in terms of the periods 0-3 months before, 0-3 
months after and 4-6 months after sending of the discontinuation letters. Patients were 
assumed to have completely discontinued use when they did not receive any 
prescription for benzodiazepines in one of the periods after sending of the 
discontinuation letters. For pharmacies which did not send any letters, the median date 
for the sending of the discontinuation letters by the other pharmacies provided a 
reference date. Only those patients who had not moved away or died during the 
observation period were included in the study by excluding all patients who had not 
been dispensed medication after the last month of follow-up. Factors possibly 
associated with the success of implementation were derived from the baseline 
inventory and from the questionnaire administered to the pharmacists for completion 
at the end of the study.
Outcomes
The primary outcome measures in this study were the percentage of GPs who reviewed 
and returned the list of long-term users and the percentage of the long-term 
benzodiazepine users to whom the discontinuation letter was sent within 4 months 
after the start of the study. Other outcome measures were the percentage of long-term 
users who managed to completely discontinue their use of benzodiazepines and the 
percentage of long-term users who reduced their use by at least 50% in months 0-3, 4-6 
and 10-12 following the sending of the discontinuation letter.
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Sample size
Assuming an average of 150 long-term benzodiazepine users per Dutch pharmacy and 
exclusion of about 30% of the long-term benzodiazepine users by the cooperating GPs 
we estimated the percentage of long-term users to whom a discontinuation letter 
would be sent (i.e., one of the primary outcomes) to be about 70% for the experimental 
group and 60% for the control group. An empirical estimate of the Intracluster 
Correlation Coefficient (ICC) from a study of benzodiazepine patients who were offered 
withdrawal was 0.0534. Accordingly, we computed that 43 clusters of pharmacies were 
required, based on a power of 0.8 to detect a significant difference (P = 0.05, two
sided)35.
Statistical analysis
The impact of the intensive implementation programme on the success of 
implementation and on prescribing patterns was examined using random coefficient 
regression models which took into account the fact that the patients were grouped 
within pharmacy clusters. The primary analysis was intention-to-treat and involved all 
of the pharmacies randomly assigned to the control and experimental groups. P-values 
of 0.05 or less were considered significant. Differences in baseline characteristics 
between the control and experimental groups and the possible determinants of 
successful implementation were tested for using unpaired t-tests and X2 tests.
Results
Participating pharmacies, lost to follow-up and data completeness 
A total of 91 pharmacies initially registered for participation in the study. One 
pharmacy was excluded before randomization because this was only an emergency 
pharmacy which did not have regular patients as a consequence of this.
Clustering on the basis of local collaboration of the remaining 90 pharmacies resulted in 
21 single pharmacy clusters, 13 two-pharmacy clusters, 6 three-pharmacy clusters, 5 
four-pharmacy clusters and 1 five-pharmacy cluster. Baseline data on 89 of the 
pharmacies and their patients were available. Questionnaire data from the pharmacists 
on the implementation process were available for 69 of the pharmacies. For the 
remaining 21 pharmacies, the success of the implementation activities could be 
established via telephone interview for 17 of them. Follow-up patient data were 
available for 79 of the pharmacies: one pharmacy did not authorize extraction of data 
from the SFK database for follow-up purposes; two pharmacies closed during follow-up; 
one pharmacy had not provided all dispensing data to the SFK in the period of follow- 
up; and seven of the pharmacies had changed their patient identification numbers in 
conjunction with the use of a new information system which precluded extraction of 
data from the SFK database for follow-up purposes.
The flow of participants through each phase of the study is depicted in Figure 1.
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Figure 1. Flow of participants through each phase of the study.
Baseline characteristics
In Table 1, an overview of those characteristics which might influence the care- 
providing function of the pharmacist and those characteristics which differed for the 
experimental and control groups are presented. Those baseline characteristics which 
did not differ for the two groups are not displayed. The pharmacies in both groups were 
comparable with regard to most characteristics with the exception of the percentage of 
prescriptions from GPs received electronically; the quality of the relations with the 
GPs; and the judged importance of the PTAM. More positive values on these
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characteristics were found for the control group when compared to the experimental 
group. More of the pharmacists in the experimental group, however, felt that the 
health insurance company was requiring study participation than in the control group.
Table 1. Baseline characteristics of participating pharmacies
Characteristic Control group 
(n=42)
Experimental 
group (n=47)
P-value
Organizational
Number of years in service of managing pharmacista 15.1 14.7b 0.820
Pharmacist trainer 10 (24) 6 (13)c 0.191
Presence of specialized technicians 28 (67) 31 (66) 0.944
Prescriptions from GP received electronically (incl. fax):
0-25% 10 (24) 12 (26) 0.002
26-50% 3 (7) 11 (23)
51-75% 4 (10) 13 (28)
76-100% 25 (60) 11 (23)
Cooperation with GPs
Quality of relation with GP
Workable/could be better/bad 3 (7) 12 (26) 0.021
Good/very good 39 (93) 35 (74)
What pharmacist thinks about importance PTAM
Very unimportant/unimportant/neutral 2 (5) 11 (23) 0.013
Important/very important 40 (95) 36 (77)
Individual patient care
Frequent participation in pharmacotherapeutic
postgraduate training
Sometimes or never 9 (21) 8 (17) 0.597
Regularly or often 33 (79) 39 (83)
Attitude towards provision of pharmaceutical cared
Least positive 0 (0) 2 (4) 0.176
Most positive 42 (100) 45 (96)
Pharmacist participated in this study because he/she felt
the insurance company forced him/her to participate 1 (2) 6 (14) 0.065
Note: Figures represent the number (and percentage in parentheses) of pharmacies unless otherwise 
specified.
a Figures represent the mean; b n= 45; c n= 46; d Attitude was measured using three statements which 
could be responded to with: completely agree, partly agree, neutral, partly disagree or completely 
disagree. Attitude was considered “least positive” when less than 2 out of the 3 statements were 
responded to with partly agree or completely agree. Attitude was considered “most positive” when at 
least 2 out of the 3 statements were responded to with partly agree or completely agree. The 
statements were: It is the task of the pharmacist to provide feedback to GPs via prescription figures; 
Informing the patient about correct use of medication is a shared responsibility of the pharmacist and 
GP; and Encouraging medication adherence is a shared responsibility of the pharmacist and GP.
An average of 272 long-term benzodiazepines users were selected per pharmacy in the 
control group and 303 in the experimental group. The baseline characteristics of the 
long-term benzodiazepine users were similar for the control and experimental groups, 
as is shown in Table 2.
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Table 2. Baseline characteristics of long-term benzodiazepine users
Characteristics of users Long-term users in Long-term users in
control group experimental
n=11429 group n=14244
Agea 65.1 (15.3) 64.7 (15.3)
% female 70.1 69.6
Baseline benzodiazepine useb 83 (90.5) [0.92] 87 (83.8) [0.97]
Patients with more than 90 DDDsc 2998 (26.2) 3955 (27.8)
Patients with more than one benzodiazepinec 2111 (18.5) 3285 (23.1)
Type of benzodiazepine
Temazepamd 22.6 21.9
Oxazepamd 15.4 13.6
Lormetazepamd 1 0.1 11.4
Diazepamd 9.9 1 0.7
Lorazepamd 8.4 1 0.2
Zopiclond 7.6 7.0
Zolpidemd 5.1 5.4
Otherd 20.9 19.8
a Mean (SD); b Mean defined daily doses (DDDs) three months prior to inclusion in study (SD) [daily use 
DDD]; c total number of patients (%); d % of DDDs
The mean age was about 65 years (SD=15.3), 70% of the users was female. Baseline use 
in the 3 months prior to inclusion was 83 DDDs (SD=90.5) for the control group and 87 
DDDs (SD=83.8) for the experimental group. Some 25% of all the long-term users used 
more than 90 DDDs (26.2% in the control group and 27.8% in the experimental group) 
while 18.5% and 23.1% of the users in the control and experimental groups, 
respectively, used more than one benzodiazepine.
Success of implementation of the intervention
The success of the implementation is shown in Table 3. The percentages of the GPs who 
reviewed and returned the list of long-term users did not differ significantly for the 
experimental versus control groups: 38% vs. 31% (P=0.409). Of all the long-term users 
included in the study 14% vs. 10% (P=0.690) received the discontinuation letter within 4 
months after the start of the study. The observed ICC was 0.39 0.48 for the binary 
measures and 0.66 0.72 for the continuous measures.
A number of other outcomes measures showed non significant results which were 
nevertheless in favour of the intensive implementation programme. More of the 
pharmacists in the experimental group (81%) than in the control group (51%, P=0.064) 
had actually provided their GPs with a list of long-term benzodiazepine users. In 
addition, more of the pharmacies in the experimental group than in the control group 
received the list of long-term benzodiazepine users for exclusion purposes from at least 
one of the cooperating GPs (72% vs. 47%, P=0.138); more of the pharmacies in the 
experimental group than in the control group sent the discontinuation letters within 
four (43% vs. 26%, P=0.370) and eight (70% vs. 40%, P=0.069) months after the start of 
the study. Eight months after the start of the study, that is, the discontinuation letter
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was sent to only 20% vs. 13% (P=0.320) of the long-term benzodiazepine users in the 
experimental and control groups, respectively.
Table 3. Indicators for success of implementation
Indicator Control group 
(n=43)
Experimental 
group (n=47)
P-value T- or F- 
value
f.d.
Pharmacies which delivered list of long-term 
users to any GPa
22 (51) 38 (81) 0.064 1.90 44
Pharmacies to which at least one GP returned 
list of long-time usersa
20 (47) 34 (72) 0.138 1.51 44
Pharmacies which sent discontinuation letters 
by 4 months after start of studya
11 (26) 20 (43) 0.370 0.91 44
Pharmacies which sent discontinuation letters 
by 8 months after start of studya
17 (40) 33 (70) 0.069 1.87 44
GPs from the PTAM group to whom a long-term 
user list was sentb
3.9 (36.1) 5.8 (52.0) 0.164 2.01 43
GPs from the PTAM group who returned long­
term user listb
3.3 (29.8) 4.1 (37.8) 0.409 0.70 43
Long-term users who received a discontinuation 23.8 (9.5) 
letter within 4 months of study startc
14 (14.4) 0.690 0.16 44
Long-term users who received a discontinuation 33.5 (12.9) 58.1 (19.9) 0.320 1.01 44
letter within 8 months of study startc
a Figures represent number (and percentage in parentheses) of pharmacies, test statistic = t-value. 
b Figures represent the mean (and mean percentage in parentheses) of total GPs participating in the 
regular pharmacotherapy audit meeting (PTAM) group, test statistic = F-value. Note that the mean for 
the total number of GPs participating in a PTAM group was 11.3 for the control group and 11.1 for the 
experimental group.
c Figures represent the mean (and mean percentage in parentheses) of long-term users in the 
pharmacies, test statistic = F-value. Note that the mean number of long-term benzodiazepine users was 
272 in the control group and 303 in the experimental group.
Changes in prescription patterns
In Table 4, the observed benzodiazepine prescription patterns for the control and 
experimental groups are presented. The percentages of patients who completely 
discontinued benzodiazepine use 0-3 and 4-6 months after the sending of the 
discontinuation letters did not differ significantly for the experimental versus control 
groups nor did the percentage of patients showing at least a 50% reduction of DDDs or 
the mean reduction of DDDs per patient. Six months after the sending of the 
discontinuation letters about 10% of the patients had completely stopped using 
benzodiazepines in both groups.
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Table 4. Prescription of benzodiazepines to 
pharmacy groups
long-term users in control and experimental
Long-term users 
in control group 
(n=7975)
Long-term users 
in experimental 
group (n=11423)
P-value
Benzodiazepines prescribed 0-3 months prior to 
sending of discontinuation lettera
79.1 81.4 0.497
Benzodiazepines prescribed 0-3 months following 
sending of discontinuation lettera
75.7 77.4 0.611
Benzodiazepines prescribed 4-6 months following 
sending of discontinuation lette a
73.4 77.2 0.175
Reduction in prescription of benzodiazepines 0-3 
months after sending of discontinuation lettera
3.4 4.0 0.716
Reduction in prescription of benzodiazepines 4-6 
months after sending of discontinuation lettera
5.7 4.2 0.174
Patients who completely discontinued use 0-3 
months after sending of discontinuation letterb
659 (8.3) 998 (8.7) 0.753
Patients who completely discontinued use 4-6 
months after sending of discontinuation letterb
810 (10.2) 1129 (9.9) 0.293
Patients who reduced use by at least 50% 0-3 
months after sending of discontinuation letterb
1179 (14.8) 1793 (15.7) 0.461
Patients who reduced use by at least 50% 4-6 
months after sending of discontinuation letterb
1331 (16.7) 1820 (15.9) 0.436
Note: Data on 79 pharmacies.
a Mean DDDs (defined daily doses) dispensed; b Number of patients (%)
Factors associated with success of implementation
Those pharmacy characteristics possibly associated with the sending of the 
discontinuation letters by the pharmacists are shown in Table 5. Only feeling forced by 
the health insurance company to participate in the study and being randomly assigned
to the experimental group were found to correlate positively with successful 
implementation of the sending of the discontinuation letters.
Table 5. Determinants of successful implementation
Pharmacies which Pharmacies P-value
did not send which sent
letters (n=39) letters (n=50)
Number of personnel is sufficient to accomplish standard 39 (100) 43 (86) 0.015
pharmacy tasks
Pharmacist encourages technicians to attend classes in 39 (100) 44 (88) 0.040
pharmaceutical care
Pharmacy is part of chain or franchise formula 31 (79) 29 (58) 0.032
Attention already paid to long-term use of benzodiazepines 10 (26) 5 (10) 0.050
in the past
What pharmacist thinks about importance PTAM
very unimportant, unimportant or neutral 2 (5) 11 (22) 0.025
important/very important 37 (95) 39 (78)
Pharmacist participated in study due to perceptions of 0 (0) 7 (14) 0.016
pressure from insurance company
Pharmacy assigned to experimental group 14 (36) 33 (66) 0.005
Figures represent number of pharmacies (%)
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In contrast, the following pharmacy characteristics were found to correlate negatively 
with successful implementation of the sending of the discontinuation letters: sufficient 
personnel to accomplish standard tasks; encouragement of technicians to attend 
pharmaceutical care classes; participation in a pharmacy chain or franchise formula; 
prior focus on long-term benzodiazepine use; and positive perceived importance of 
PTAM.
Effect of the discontinuation letter
In Table 6 those pharmacies which sent discontinuation letters are compared to those 
which did not. The percentage of patients who completely discontinued their use of 
benzodiazepines during the first 3 months after the sending of the discontinuation 
letters was significantly higher for the group of pharmacies which actually sent the 
letters. However, 4-6 months after the sending of the discontinuation letters, the two 
groups of pharmacies no longer differed with respect to the percentages of patients not 
receiving any benzodiazepine prescription. Similarly, significant differences were found 
in the mean reductions of the DDDs and the percentages of patients who reduced their 
use of benzodiazepines by at least 50% in the first 3 months after the sending of the 
discontinuation letters but not in the 4-6 months after.
Table 6. Prescription of benzodiazepines to long-term users in pharmacies which did and did not 
send discontinuation letters
Long-term users in Long-term users in P-value 
pharmacies which pharmacies which 
did not send any sent letters 
letters (n=7824)a (n=11574)b
Benzodiazepines prescribed 3 months prior to sending 
of discontinuation letterc
79.9 80.8 0.273
Benzodiazepines prescribed 0-3 months after sending 
of discontinuation letterc
78.5 75.4 0.569
Benzodiazepines prescribed 4-6 months after sending 
of discontinuation letterc
76.1 75.3 0.561
Reduction in prescription of benzodiazepines 0-3 
months after sending of discontinuation letterc
1.4 5.4 <0.001
Reduction in prescription of benzodiazepines 4-6 
months after sending of discontinuation letterc
3.8 5.5 0.257
Patients who completely discontinued use 0-3 months 
after sending of discontinuation letterd
566 (7.2) 1091 (9.4) 0.047
Patients who completely discontinued use 4-6 months 
after sending of discontinuation letterd
686 (8.8) 1253 (10.8) 0.544
Patients who reduced use by at least 50% 0-3 months 
after sending of discontinuation letterd
965 (12.3) 2007 (17.3) <0.001
Patients who reduced use by at least 50% 4-6 months 
after sending of discontinuation letterd
1133 (14.5) 2018 (17.4) 0.051
Data on 79 pharmacies. a For the pharmacies which did not send any letters, the median date for the 
sending of letters by the other pharmacies provided a reference date; b Of the 11,574 long-term users in 
the pharmacies which sent letters, to 29.8% a discontinuation letter was sent; c Mean DDDs (defined daily 
doses) dispensed; d Number of patients (%).
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Discussion
More than one third of the pharmacies in the control group, which received minimal 
support, had sent the discontinuation letter within 8 months of the start of the study. 
In the experimental group about two thirds of the pharmacies had done this, which 
shows some 30% of the pharmacies in the experimental group to benefit from the 
provision of intensive implementation support. For yet another 30% of the pharmacies 
in the experimental group, however, the discontinuation letters were simply not sent 
despite intensive support.
The primary outcomes - namely the percentage of GPs who reviewed and returned the 
list of long-term users of benzodiazepines to the pharmacy and the percentage of long­
term users receiving a discontinuation letter within four months of the start of the 
study - did not differ for the experimental versus control groups. More of the 
pharmacists in the experimental group nevertheless supplied the cooperating GPs with 
patient lists than in the control group: 81% vs. 51%, respectively. While nearly all of the 
GPs who received a patient list in the control group also reviewed and returned this list 
to the pharmacist, a substantial part of the GPs in the experimental group did not 
return the patient list despite having received it. This may be explained by differences 
in the baseline characteristics of the experimental versus control groups which were 
less good (on average) in the experimental group, which possibly created a type 2 
error. That is, when compared to the pharmacists in the control group, the pharmacists 
in the experimental group may have delivered the patient lists to more GPs with whom 
the cooperation was not so good with a relatively smaller percentage of the GPs in the 
PTAM thus returning the patient lists to the pharmacists in the experimental group than 
in the control group. The percentage of long-term users to whom the pharmacists sent 
a discontinuation letter in collaboration with the GP, in other words, did not reflect the 
presentation of the patient lists to more GPs of the pharmacists in the experimental 
group.
The finding of a substantial difference in the percentages of the control versus 
experimental pharmacies which had sent discontinuation letters by eight months after 
the start of the study is particularly promising in light of the fact that the difference 
between the study groups was not significant 4 months earlier. This suggests that the 
intensive implementation support programme may have been particularly helpful for 
those pharmacies which had difficulties getting started and/or carrying out the 
intervention.
Several pharmacy characteristics were negatively related to the sending of the 
discontinuation letters by the pharmacists in cooperation with the GPs. A prior focus on 
benzodiazepine use may have decreased the motivation of pharmacists and GPs to work 
with this category of patients again, for example. Similarly, participation in a pharmacy 
chain or franchise formula presumably involves additional activities, which may have 
had higher priority for the pharmacist. Some of the other negative relations are more
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difficult to understand. Sufficient personnel to accomplish standard tasks is one of 
these factors, for example, as lack of time and personnel is generally mentioned by 
health care workers as a reason for unsatisfactory implementation of patient care 
improvements. Similarly, we expected encouragement of technicians to attend 
pharmaceutical care classes to positively affect implementation as we assumed this 
characteristic to reflect the more general importance of quality pharmaceutical care 
for the pharmacist. It is thus possible that these findings may be spurious as a large 
number of variables was analyzed (i.e., chance capitalization). Future research is 
necessary to gain greater insight into these findings.
The present study obviously has a number of strengths and weaknesses. Among the 
strengths are the randomized design, large sample size and low drop-out rates for the 
pharmacies in addition to the high degree of validity for the prescription data 
extracted from the SFK-database. One weakness was that of the 305 pharmacies invited 
for participation, 214 did not respond to our invitation. Unfortunately, we were not 
able to determine if the characteristics or level of pharmaceutical care in the non­
responding pharmacies were comparable to those in the pharmacies which responded. 
We did not know the reasons why pharmacies chose not to participate either. Whether 
the voluntary participation might have lead to bias is therefore unclear. A second 
weakness was the use of self-report measures to assess implementation of the 
intervention. Another weakness, which we discovered only after completion of the 
study, was that the observed Intracluster Correlation Coefficient (ICC) was about ten 
times higher than expected. This high ICC was mainly due to the fact that so many of 
the pharmacy clusters did not send discontinuation letters: In these clusters, the p = 1, 
which means that the effective sample size for these pharmacy clusters is reduced to 
the number of these clusters. A post hoc power calculation showed that 357 clusters of 
pharmacies (i.e., about 700 pharmacies with 300 long-term benzodiazepine users each) 
would have been required to detect a significant difference. We therefore suggest that 
the absolute differences between the groups be considered in the interpretation of the 
results.
Interventions targeted at health care providers, whether multifaceted or single, show 
substantial variation in the level of change achieved26,36,37. A large review with 235 
trials found a median effect of 9% change on measures of professional performance26. It 
is also often therefore suggested that carefully tailored interventions are more likely to 
target specific barriers to change37. However, Shaw et al.39 found only mixed results 
and concluded that it is still unclear whether specially tailored strategies are more 
effective than non-tailored strategies or no special strategy. The tailored intervention 
in the present study resulted in a relatively large improvement of pharmacist 
performance. Nevertheless, the main barrier expected on the basis of the baseline 
inventory and the interactive educational meeting - namely, the cooperation with the 
GPs - was indeed found to be a major problem for the pharmacists in this study. Use of
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a more elaborate intervention to enhance the cooperation between pharmacist and GPs 
was assumed to go too far, however, and also be too expensive when compared to the 
relatively simple intervention used in this study. The results of the present study thus 
show better collaboration between pharmacists and GPs to be vital for optimal 
pharmacotherapeutic treatment of patients. Although GPs have been found to generally 
appreciate the pharmacist’s advising of patients with regard to their medication and 
any drug-related problems33,40-42, many GPs are less enthusiastic about this when it 
leads to interference with prescription decisions42. Earlier studies have also clearly 
shown room for improvement in the communication and cooperation of pharmacists and 
GPs41,43.
In the present study, the effects of a discontinuation letter on general practice 
prescription patterns were studied as opposed to the effects of the letter on individual 
patients. Given that the efficacy of such a discontinuation letter was assumed to be 
adequately demonstrated in previous studies, the focus of our study was on the wide- 
scale implementation of such a pharmaceutical care practice. In the previous studies, 
between 71% and 100% of the long-term users in the intervention groups received a 
discontinuation letter. In the present study, in contrast, the pharmacists in the 
experimental group only managed to send a discontinuation letter to 30% of their long­
term benzodiazepine users and then mainly due to limited professional cooperation on 
the part of the GPs. In other words, the reach of the present intervention appeared to 
be reduced remarkably by the study setting.
The size of the effect of the discontinuation letter observed in previous studies using 
such an intervention11-13 was not observed in the present study. If we extrapolate from 
the results of Gorgels et al.11, we can expect about 5% more of the long-term users in 
those pharmacies which sent discontinuation letters to discontinue their 
benzodiazepine use than in those pharmacies which did not send discontinuation 
letters. Even such small but clinically relevant effect was not found in the present 
study. It is possible that some of the patients who actually discontinued their 
benzodiazepine use were excluded from the present evaluation because they had no 
medication dispensed after the last month of follow-up. However, such 
underestimation of discontinued use can be assumed to be similar across pharmacies 
including those which did not and those which did send discontinuation letters and 
therefore not affect the present findings differentially. Given that the baseline 
characteristics of the patients were comparable to those of patients in previous 
studies, and that the discontinuation letter was about the same, there is no obvious 
explanation for the lack of an effect in the present study.
It is possible that attention to the reduction of long-term benzodiazepine use in the 
past had already led to reduced benzodiazepine prescription practices by the start of 
the present intervention. The number of patients to be actually targeted by the 
discontinuation letter (i.e., those patients who may be able to discontinue their
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benzodiazepine use rather easily) could thus have been reduced prior to the sending of 
the letters. This possibility is supported by the general finding that the volume of 
benzodiazepine prescriptions in The Netherlands - in terms of DDDs - had decreased by 
4% between 2001 and 20061.
As the added effect of additional consultation with a GP has been found to be low in 
other research11, and the discontinuation letter was signed by both the pharmacist and 
the GP in the present study, we do not think that the lack of an effect in the present 
study can be attributed to the coordinating role of the pharmacist and not the GP in 
this study. However, this possibility cannot be ruled out and might be considered in 
future research.
In conclusion, an intervention to reduce long-term benzodiazepine use should be shown 
to be effective not only in clinical studies (i.e., under highly controlled conditions) but 
also in daily practice. A substantial number of the pharmacies in the present study 
were found to implement the letter intervention with minimal support. An intensive 
implementation support programme aimed at pharmacists was found to stimulate care 
activities in the pharmacies but not reach the long-term benzodiazepine users 
identified at the start of the study. A key factor in this appears to be the limited 
professional contribution of the cooperating GPs which is certainly a topic for future 
research. The present results do not confirm the effectiveness of a discontinuation 
letter for the reduction of long-term benzodiazepine use, which means that the 
relevance of wide-scale use of such a letter is still open to question and thus requires 
further evaluation. Considerable attention should also be paid in future research to the 
initial decision to prescribe benzodiazepines for a longer period than recommended.
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Abstract
Rationale, aims and objectives: Patients with atherothrombotic cardiovascular disease 
(ACD) should receive specific treatments, including lipid-lowering medication. In order 
to optimize treatment for patients with ACD in primary care, an efficient method to 
identify all these patients is needed. We aimed to assess which method serves best to 
identify all patients with ACD in Dutch primary care: morbidity records, antiplatelet 
prescribing records or a combination of these.
Method: In a cross-sectional study in 45 Dutch general practices, computerized medical 
records of all patients with any cardiovascular disease, cardiovascular symptoms or 
cardiovascular medication were analyzed.
Results: Of the 7280 patients with a recorded indisputable indication for antiplatelet 
therapy, 4715 (64.8%) could be identified by means of antiplatelet prescriptions. Of the 
patients with a recorded indisputable indication for antiplatelets but without any 
antiplatelet prescription, 28.9% received a vitamin K antagonist. Of the 8718 patients 
with antiplatelet therapy, 5697 (65.3%) could be identified by means of a recorded 
indisputable or possible indication for antiplatelet therapy. Female patients, patients 
younger than 60 years old, and patients having a recorded diagnosis of angina pectoris 
or diabetes had a higher risk to be missed by antiplatelet prescribing records. 
Conclusion: Morbidity records and prescribing records should be used both in order to 
identify all patients with ACD in primary care. Patients who use antiplatelet 
prescriptions but do not have a recorded ACD deserve extra attention, because they are 
either treated without a good indication for antiplatelet therapy (over-treatment) or 
need a correction of their morbidity records.
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Introduction
Following the advice of the Third Joint Task Force of European and other societies on 
cardiovascular disease prevention in clinical practice1, a Dutch guideline on 
cardiovascular risk management, with an integrated approach of relevant risk factors, 
was published in January 2006 for the first time2. Relatively new in this guideline is the 
recommendation to prescribe statins to all patients with ACD, unless LDL cholesterol 
levels are below 2.5 mmol/L (100 mg/dl). As a consequence, the number of patients 
eligible for treatment with statins increased. In order to optimize statin prescribing for 
patients with ACD, an efficient method to identify these patients is required.
An obvious way to identify patients with ACD would exist of an automated selection on 
the basis of a recorded diagnosis of ACD in the general practice morbidity records. 
However, from previous studies it is known that general practice morbidity records are 
generally not complete3-5. Another method frequently used to identify specific patient 
groups is to use drug prescribing or dispensing records. Table 1 presents medication 
recommended for various cardiovascular diseases. Because all patients with ACD should 
be treated with antiplatelet therapy (low-dose aspirin or other oral antiplatelet drugs), 
except when comorbidity requires the prescribing of a vitamin K antagonist, prescribing 
records of antiplatelets could be a convenient tool to identify patients with ACD who 
are eligible for statin therapy.
Table 1. Recommendation on drug therapy in cardiovascular disease in prevailing Dutch primary care 
guidelines
Cardiovascular disorder ACE/-inhibitor/ Acetylsalicylic Beta Diuretic Organic Statin Various 
angiotensin II- acid or other blocking nitrate other
antagonist thrombocyte agent drugs
aggregation 
inhibitor
Angina pectoris 1 2
Myocardial infarction 2 1 1
Heart failure3 1 2 2 1
TIA 2
Stroke 2
Peripheral arterial disease 1
Atrial fibrillation 2 2
Diabetes mellitus type II 1 2 2 2
ACE, angiotensin-converting enzyme; TIA, transient ischemic attack
1 Medication recommended for all patients with this condition.
2 Medication recommended for specific patients with this condition.
aThe Dutch guideline on cardiovascular risk management includes heart failure on the basis of coronary 
heart disease only.
The aim of this study was to compare the appropriateness of morbidity records of ACD 
and prescribing records of antiplatelet drugs, or both, for the identification of patients 
with ACD in Dutch general practice.
1 1 2 
2 1 2 
2 2 
1 2  
1 2  
1 2 
2
2 2
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Methods
Design and setting
The present study was a cross-sectional study. Data had been routinely obtained from 
45 of all 85 general practices in a computerized GP-based network in the Netherlands, 
i.e. the National Information Network of General Practice (LINH). In the LINH network, 
the GP staff routinely records encoded patient information on contacts, prescriptions 
and referring using a computerized medical record system in which facilities are 
present to support valid and complete registration. An extensive quality control check 
with regard to internal consistency and completeness of registration is performed 
before the general practice data are entered into the LINH database. Additionally, 
general practices receive feedback on the quality of the data they provided for the 
database twice a year in order to optimize registration quality. The network reflects 
the national distribution of Dutch general practices and the Dutch population by age 
and sex6.
The 45 practices were selected on the basis of completeness of registration: for each 
practice, the total number of morbidity and prescription records in 2006 were 
determined. Practices were excluded if: (1) in one of the quarters of the year, less 
than 10% of the total morbidity and prescription records in 2006 were present; (2) an 
ICPC-code was recorded for less than 50% of the morbidity records. The general 
practices in this study were similar in practice type (i.e. single handed, duo or group 
practice, and urban character) compared to all LINH practices. Compared to all Dutch 
practices, the percentage of the 45 LINH practices in areas with less than 1000 or with 
more than 2500 addresses per km2 was higher than expected from the national 
distribution7.
Study population
Patients were included if they had at least one International Classification of Primary 
Care (ICPC) code recorded for cardiovascular complaints or disease (K00 through K29; 
K70 through K99) in the morbidity or prescription records between 2004 and 2006, 
and/or at least one prescription in the prescription records with Anatomical 
Therapeutic Chemical (ATC) code8 B01A (antithrombotic agents), or C (cardiovascular 
system) in the period between January and December 2006. Patients were excluded if 
they were not registered in the GP practice in the entire period from January 1st 2004 
through December 31st 2006, unless they had been registered before January 1st 2004 
and had died between 2004 and 2006.
Measures
Patients were assumed to have an indisputable indication for antiplatelet therapy on 
the basis of prevailing clinical guidelines if they had a recorded ICPC code K74 (angina 
pectoris), K75 (acute myocardial infarction), K76 (other chronic ischemic disease, e.g.
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coronary sclerosis or myocardial infarction > 4 weeks ago), K89 (transient ischemic 
attack (TIA)), K90 (stroke), or K91 (atherosclerosis). On the basis of clinical guidelines 
and their interpretation by cardiovascular experts, patients were assumed to have a 
possible but not indisputable indication for antiplatelet therapy if they had a recorded 
ICPC code K77 (heart failure), K78 (atrial fibrillation), K83 (non-rheumatic valvular 
heart disease, e.g. aorta stenosis, mitralis insufficiency), K92 (other disease of 
peripheral arteries, e.g. peripheral arterial disease), or K99 (other disease of the 
cardiovascular system, e.g. aortic aneurysm). The period 2004-2006 was used to 
identify the indication diagnoses.
Patients were assumed to be on antiplatelet therapy if they had at least one 
prescription for a platelet aggregation inhibitor (ATC code B01AC) recorded in 2006. 
Patients were assumed to be on a vitamin K antagonist if they had at least one 
prescription for medication with ATC B01AA in 2006. Prescriptions for vitamin K 
antagonists were considered to be a justification for an absence of antiplatelet 
prescriptions in patients with atherothrombotic cardiovascular disease.
Statistical analysis
Descriptive analysis was done to determine the percentages of patients in different 
subgroups which received antiplatelet therapy. Factors related to non-prescribing of 
antiplatelet therapy to patients with an indisputable indication for antiplatelets were 
evaluated using random coefficient logistic regression analysis, with general practice as 
random factor. All analyses were performed using the SPSS 16.0 software package 
except the random coefficient logistic regression analysis, which was performed using 
the SAS 9.1.3 software by means of the GLIMMIX procedure. A two-sided p-value <0.05 
was assumed to be significant.
Results
A total of 45739 eligible patients were identified; 20246 (44.3%) were male with a mean 
age of 57.3 years old, mean age of the women was 57.8 years old. In total, 33819 
prescriptions with ATC B01AC were found, which is on average 3.8 prescriptions for 
each patient with antiplatelet therapy in 2006. The number of prescriptions for each 
antiplatelet drug is shown in Table 2.
Table 2. Prescriptions for platelet aggregation inhibitors in The Netherlands
ATC Name Number of prescriptions in 2006 (% of all B01AC)
B01AC04 Clopidogrel 1630 (4.B)
B01AC06 Acetylsalicylic acid 15300 (45.2)
B01AC07 Dipyridamole 2319 (6.9)
B01AC0B Carbasalate calcium 13B03 (40.B)
B01AC30 Acetylsalicylic acid + dipyridamole 767 (2.3)
ATC, Anatomical Therapeutic Chemical code
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Table 3 shows the percentage of patients with or without at least one antiplatelet or 
vitamin K antagonist prescription in 2006. Of the patients with a recorded indisputable 
indication for antiplatelet therapy, 64.8% received at least one antiplatelet 
prescription in 2006. Patients with a recorded ICPC code for TIA were most likely and 
patients with a recorded ICPC code for angina pectoris were least likely to be identified 
by means of antiplatelet therapy: 74.4% and 59.1%, respectively. Of the patients with a 
recorded indisputable indication for antiplatelets but without any antiplatelet 
prescription, 28.9% received a vitamin K antagonist. Of the patients with a recorded 
indisputable indication for antiplatelets, 25.1% did not receive any antithrombotic 
prescription in 2006. Of the patients who received one or more antiplatelet 
prescriptions, 54.1% had a recorded indisputable indication; 11.3% had recorded a 
possible indication; and 34.7% did not have a recorded indisputable or possible 
indication for antiplatelet therapy. Of all patients in our study population without a 
recorded possible or indisputable indication for antiplatelet therapy, 8.7% did receive 
at least one antiplatelet prescription in 2006. Patients in this group received 
antiplatelet therapy most frequently in case of a diagnosis of other cardiac disease 
(24.0%) or hypertension with organ damage (42.7%). Of the patients without any record 
with a cardiovascular ICPC code, an ICPC code for lipid metabolism disorders, or an 
ICPC code for diabetes, 16.1% received antiplatelet therapy.
Factors associated with antiplatelet prescriptions for patients with an indisputable 
indication are shown in Table 4. Women were less likely to receive antiplatelet therapy 
than men; older patients received antiplatelet medication more often than younger 
patients. Patients with a recorded diagnosis of angina pectoris or diabetes were less 
likely to receive antiplatelet therapy than patients without a record of these diagnoses.
Table 3. Patients with or without at least one antiplatelet or vitamin K antagonist prescription in 2006
ICPC code Nr of patients 
with antiplatelet 
therapy (%)
Nr of patients 
without 
antiplatelet 
therapy (%)
Nr of patients 
without antiplatelet 
therapy with vitamin 
K antagonist (%)
Nr of patients without 
any prescription for 
antiplatelets or vitamin 
K antagonists (%)
All patients 8718/45739 (19.1) 37021/45739 (80.9) 2406/37021 (6.5) 34615/45739 (75.7)
Recorded indisputable indication for antiplatelet therapy 
(K74, 75, 76, 89, 90 and/or 91)
4715/7280 (64.8) 2565/7280 (35.2) 741/2565 (28.9) 1824/7280 (25.1)
K74: angina pectoris 1949/3296 (59.1) 1347/3296 (40.9) 366/1347 (27.2) 981/3296 (29.8)
K75: acute myocardial infarction 702/1023 (68.6) 321/1023 (31.4) 124/321 (38.6) 197/1023 (19.3)
K76: other chronical ischemical disease 946/ 1316 (71.9) 370/1316 (28.1) 135/370 (36.5) 235/1316 (17.9)
K89: TIA 856/1151 (74.4) 295/1151 (25.6) 76/295 (25.8) 219/1151 (19.0)
K90: stroke a 987/1468 (67.2) 481/1468 (32.8) 139/481 (28.9) 342/1468 (23.3)
K91: atherosclerosis 179/255 (70.2) 76/255 (29.8) 30/76 (39.5) 46/255 (18.0)
Recorded possible but no indisputable indication for 
antiplatelet therapy (K77, K78, 83, 92 and/or 99)
982/3579 (27.4) 2597/3579 (72.6) 905/2597 (34.8) 1692/3579 (47.3)
K77: heart failure 306/1193 (25.6) 887/1193 (74.4) 317/887 (35.7) 570/1193 (47.8)
K78: atrial fibrillation 248/1258 (19.7) 1010/1258 (80.3) 618/1010 (61.2) 392/1258 (31.2)
K83: non-rheumatic valvular disease 49/290 (16.9) 241/290 (83.1) 89/241 (36.9) 152/290 (52.4)
K92: other disease peripheral arteries, e.g. peripheral 
arterial disease
382/845 (45.2) 463/845 (54.8) 80/463 (17.3) 383/845 (45.3)
K99: other disease cardiovascular system, e.g. aneurysm 
aortae
108/456 (23.7) 348/456 (76.3) 41/348 (11.8) 307/456 (67.3)
Recorded indisputable or possible indication for 
antiplatelet therapy (One or more of all the ICPCs above)
5697/10859 (52.5) 5162/10859 (47.5) 1646/5162 (31.9) 3516/10859 (32.4)
No recorded indisputable or possible indication for 
antiplatelet therapy
3021/34880 (8.7) 31859/34880 (91.3) 760/31859 (2.4) 31099/34880 (89.2)
K01-K29: cardiovascular complaints 727/9087 (8.0) 8360/9087 (92.0) 163/8360 (1.9) 8197/9087 (90.2)
K84: other cardiac disease 63/262 (24.0) 199/262 (76.0) 26/199 (13.1) 173/262 (66.0)
K86: essential hypertension without organ damage 1230/13179 (9.3) 11949/13179 (90.7) 229/11949 (1.9) 11720/13179 (88.9)
K87: hypertension with organ damage/secondary 
hypertension
406/950 (42.7) 544/950 (57.3) 52/544 (9.6) 492/950 (51.8)
Other cardiovascular ICPC-codes without antiplatelet 
indication
516/11491 (4.5) 10975/11491 (95.5) 318/10975 (2.9) 10657/11491 (92.7)
T93: lipid metabolism disorders 611/4438 (13.8) 3827/4438 (86.2) 108/3827 (2.8) 3719/4438 (83.8)
T90: diabetes 746/4496 (16.6) 3750/4496 (83.4) 121/3750 (3.2) 3629/4496 (80.7)
None of these 464/2889 (16.1) 2425/2889 (83.9) 122/2425 (5.0) 2303/2889 (79.7)
ICPC, International Classification of Primary Care; TIA, transient ischemic attack
a Stroke is an indisputable indication for antiplatelets for the 80% of strokes due to ischemia, and not for the 20% of strokes due to hemorrhage.
Table 4 . Factors associated with prescription of antiplatelet therapy in patients with a recorded indisputable indication for antiplatelet therapy 
without a prescription for a vitamin K antagonist.
All patients with an Patients who did 
indisputable receive
indication without a antiplatelet 
vitamin K antagonist therapy (%)
(%) (n=6315) (n=4491)
Sex
Male 3460 (54.8) 2582 (57.5) 878 (48.1) (Reference) (Reference)
Female
Age
59 years or younger
2855 (45.2) 1909 (42.5) 946 (51.9) 0.69 (0.62-0.77)a 0.60 (0.52-0.69)3
1684 (26.7) 1073 (23.9) 611 (33.5) (Reference) (Reference)
60-74 years 2565 (40.6) 1924 (42.8) 641 (35.1) 1.71 (1.50-1.95)a 1.47 (1.23-1.74)a
75 years or older 2066 (32.7) 1494 (33.3) 572 (31.4) 1.49 (1.30-1.71 )a 1.94 (1.62-2.34)3
Other medication
Oral blood glucose lowering drugs 819 (13.0) 682 (15.2) 137 (7.5) 2.21 (1.82-2.67)a Not in equation
Insulins 300 (4.8) 250 (5.6) 50 (2.7) 2.09 (1.54-2.85)a Not in equation
Organic nitrates 1458 (23.1) 1237 (27.5) 221 (12.1) 2.76 (2.36-3.22)a 2.32 (1.89-2.84)3
Other cardiac therapy 153 (2.4) 109 (2.4) 44 (2.4) 1.01 (0.71-1.43) Not in equation
Diuretics 2127 (33.7) 1693 (37.7) 434 (23.8) 1.94 (1.71 -2.19)a Not in equation
Beta blocking agents 2908 (46.0) 2511 (55.9) 397 (21.8) 4.56 (4.02-5.17)a 2.94 (2.51 -3.44)a
Calcium channel blockers 1238 (19.6) 1058 (23.6) 180 (9.9) 2.82 (2.38-3.33)a 1.90 (1.55-2.33)a
Agents acting on the renin-angiotensin system 2314 (36.6) 1961 (43.7) 353 (19.4) 3.23 (2.84-3.68)a 1.56 (1.33-1.82)a
Other antihypertensives 59 (0.9) 43 (1.0) 16 (0.88) 1.09 (0.61-1.94) Not in equation
Statins 3345 (53.0) 3010 (67.0) 335 (18.4) 9.03 (7.90-10.3)a 7.93 (6.59-9.55)a
Other lipid modifying agent 198 (3.1) 176 (3.9) 22 (1.2) 3.34 (2.14-5.22)3 Not in equation
Cardiovascular morbidity
K74: angina pectoris 2833 (44.9) 1852 (41.2) 981 (53.8) 0.60 (0.54-0.67)3 0.51 (0.43-0.61)a
K75: acute myocardial infarction 848 (13.4) 651 (14.5) 197 (10.8) 1.40 (1.18-1.66)a Not in equation
K76: other chronical ischemical disease 1126 (17.8) 891 (19.8) 235 (12.9) 1.67 (1.43-1.96)a Not in equation
K89: TIA 1035 (16.4) 816 (18.2) 219 (12.0) 1.63 (1.39-1.91 )a 2.61 (2.11-3.24)a
K90: stroke 1281 (20.3) 939 (20.9) 342 (18.8) 1.15 (1.00-1.32) 1.83 (1.50-2.23)3
K91: atherosclerosis 206 (3.3) 160 (3.6) 46 (2.5) 1.43 (1.02-1.99)a 1.62 (1.08-2.42)3
Comorbidity
Diabetes in morbidity records 1350 (21.4) 1040 (23.2) 310 (17.0) 1.47 (1.28-1.69)a 0.63 (0.51 -0.77)a
Lipid metabolism disorders in morbidity 1894 (30.0) 1590 (35.4) 304 (16.7) 2.74 (2.39-3.14)a Not in equation
records
Patients who 
did not receive 
antiplatelet 
therapy (%) 
(n=1824)
OR for treatment 
with antiplatelets 
(95%  Cl) in 
bivariate analysis
OR for treatment 
with antiplatelets 
(95%  Cl) in multilevel 
multivariate analysis
TIA, transient ischemic attack; a Significant effects (p<0.05)
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Discussion
By using GPs’ prescribing records, with antiplatelet therapy as a potential marker of 
ACD, about two thirds of the patients with a recorded ACD were identified. This implies 
that a third of the patients with ACD would be missed if their identification would 
depend on prescribing records. The other way around, only about half of the patients 
with a prescription of antiplatelet therapy had a recorded indisputable ACD and one 
third of the patients with antiplatelet therapy did not have an indisputable nor a 
possible indication for antiplatelets. These patients would be missed if their 
identification would depend on ACD morbidity records. So, neither of the two methods 
was sufficient to identify all patients with ACD.
Female patients, patients younger than 60 years old, and patients having a recorded 
diagnosis of angina pectoris or diabetes had a higher risk to be missed by antiplatelet 
prescribing records. It is unclear to what extent the large number of patients with 
antiplatelet therapy who would be missed by means of morbidity records reflects 
overprescribing of antiplatelet drugs (which are not advised for primary prevention in 
the Netherlands), or incomplete registration of ACD diagnoses. We could not find any 
publications reporting antiplatelet overprescribing. It appears that little has been 
published on this subject.
The results of our study regarding antiplatelet prescription rates for the total patient 
population with ACDs were more or less comparable to those of earlier studies in 
patients with specific ACDs9-15. Our results with respect to the factors associated with 
underprescribing and overprescribing of antiplatelet agents in patients with recorded 
ACD were in line with previous studies in which women and younger patients received 
less antiplatelet therapy than men and older patients, respectively16’17, and patients 
with a diagnosis of angina pectoris received less antiplatelet therapy than patients with 
other ACDs12.
Our study was not without limitations. The 45 GP practices in our study were not 
entirely similar to all Dutch practices and the situation may have changed since 2006. 
However, as our study led to more or less comparable results regarding antiplatelet 
prescription rates for patients with ACDs as many other studies in patients with 
different ACDs, we expect the representativeness of the practices to be satisfactory. 
With regard to the completeness of the data, both morbidity and prescription records 
are important. Since Dutch GPs generally take care of the repeat prescriptions once 
treatment has been initiated by a medical specialist and low-dose antiplatelets are 
rarely if ever dispensed over the counter in the Netherlands, we expect the 
prescription records to be sufficiently complete in our study. Next, although much 
attention is given to the quality and completeness of data in the LINH network, the 
recording of ACD morbidity may very well have been imperfect. Finally, we did not 
have any information on contraindications or intolerance for antiplatelet drugs. As 20% 
of strokes are due to hemorrhage18, antiplatelets are contraindicated for these
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patients. For other patients with a contraindication for acetylsalicylic acid, prescribing 
of clopidogrel is advised. For patients with a contraindication or intolerance for both 
acetylsalicylic and clopidogrel, underprescribing of antiplatelet therapy might have 
been overreported in this study.
In conclusion, morbidity records and prescribing records should be used both in order to 
identify all patients with ACD in general practice. Patients who use antiplatelet 
prescriptions but do not have a recorded ACD deserve extra attention, because they are 
either treated without a good indication for antiplatelet therapy (overtreatment) or 
need a correction of their morbidity records.
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Abstract
Background: Although statins have indisputably proven to reduce fatal and nonfatal 
events in patients with cardiovascular disease, many patients with established 
cardiovascular disease do not receive them. Research into the effective and efficient 
implementation of current guidelines on secondary prevention is therefore needed. 
Design: A cluster randomized implementation trial was conducted between September 
2006 and February 2008.
Methods: Experimental pharmacists received an intensive implementation programme, 
whereas control pharmacists received an educational manual only. Pharmacists in both 
the groups were asked to identify eligible patients and to provide general practitioners 
(GPs) with lists of these patients. Physicians received instructions from the pharmacists 
to review the patients regarding a statin indication and to start a statin when they 
considered this as appropriate. Main outcome measure was the percentage of identified 
patients who received one or more statin prescriptions at 6 months follow-up.
Results: Although twice as many patients were reviewed for a statin indication by a GP 
in the experimental group (19.7 vs. 10.8%, P=0.023), an equally low number of patients 
in the experimental group and the control group received statins (5.8 vs. 5.3%, 
P=0.104).
Conclusion: The intensive implementation programme had an impact on pharmacists 
and GPs, but did not result in more patients receiving statins.
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Introduction
A guideline of the Dutch College of General Practitioners (NHG)1 that was published in 
January 2006 for the first time recommends treatment with statins for patients with 
established cardiovascular disease (CVD) whose low-density lipoprotein concentrations 
are above 2.5 mmol/l (100 mg/dl). Yet a quarter to a third of Dutch outpatients with 
established CVD is still not treated with a statin2. Similar, worse or only slightly better 
percentages of nontreated patients have been observed in other European countries3-5. 
These results show that better insight into the effective and efficient implementation 
of guidelines on cardiovascular risk management is essential. As successful 
implementation generally requires a comprehensive approach, in which barriers and 
facilitators to change in a specific setting are targeted6, we developed an intensive 
implementation programme directed at pharmacists that consisted of an educational 
manual, an interactive educational meeting, reminder and feedback telephone calls 
and reminder newsletters.
The aim of this study was to test the hypothesis that this intensive programme would 
improve the implementation of appropriate prescribing of statins to eligible patients.
Methods
A cluster randomized trial was conducted between September 2006 and February 2008. 
The medical ethical committee Arnhem-Nijmegen gave approval for this trial.
Setting
In The Netherlands, all patients have an obligatory health insurance, which covers most 
medication and all patients are registered to a single general practitioner (GP) who has 
a gatekeeper role in coordinating medical care. Most patients are also registered in a 
single pharmacy, although this is not obligatory; patients can get their prescriptions in 
any pharmacy they like. Nonetheless, pharmacy shopping behaviour was very limited at 
the time of this study in The Netherlands7 and all prescriptions are routinely registered 
in the pharmacy computer system. Pharmacists do not routinely receive information on 
indications for prescribed drugs in The Netherlands and they cannot independently or 
complementary prescribe drugs. As GPs’ morbidity records are an imperfect source for 
the identification of patients who are likely to have CVD2, the pharmacy computer 
system provides an additional resource for the identification of these patients and for 
the monitoring of statin prescribing.
Most pharmacists and GPs in The Netherlands take part in pharmacotherapy audit 
meetings (PTAMs), which are held an average of five or six times a year to discuss 
pharmacotherapy topics, often on the basis of GP prescription data8. PTAM groups 
generally involve one pharmacist with a minimum of three GPs and a maximum of 12 
persons9.
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Participating pharmacies
Community pharmacies were recruited through mailing to all 211 pharmacies in the 
South of The Netherlands in April 2006. Participation was voluntary, though encouraged 
by one of the two major health insurance companies in this part of The Netherlands: 
pharmacies participating in this study were exempted from presenting an annual plan 
and from reporting of patient care activities, which is normally required for a pharmacy 
to obtain full reimbursement of medication dispensed.
There was no financial incentive for participation in the project other than the usual 
dispensing fee per prescription.
Randomization
To avoid that pharmacies in the control group would benefit from the intensive 
implementation programme through collaboration with pharmacies in the experimental 
group, we clustered such collaborations of pharmacies before randomization. There 
were 17 clusters of one pharmacy, 10 clusters of two pharmacies, six clusters of three 
pharmacies, three clusters of four pharmacies and one cluster of five pharmacies. The 
(clustered) pharmacies were numbered by a research assistant. An independent 
statistician performed a block randomization, in which each block consisted of two 
pharmacy clusters and in which the cluster size (number of pharmacies in each cluster) 
was balanced.
Interventions 
D ir ec t e d  a t  p a t ie n t s
In all participating pharmacies, both in the experimental and in the control groups, 
patients were automatically selected in the pharmacy computer system if they had at 
least one prescription for an antiplatelet drug (Anatomical Therapeutic Chemical 
classification B01AC) in the 12 months preceding the moment of selection, without any 
prescription for a lipid-modifying agent (Anatomical Therapeutic Chemical C10) in the 
same period10. As anti-platelet drugs are recommended only for patients with 
established CVD in The Netherlands1, selected patients were all likely to have 
established CVD and thus they all had a potential statin indication. In a PTAM with GPs, 
pharmacists discussed the national guideline ‘Cardiovascular risk management’1 and 
handed over a gross list of eligible patients to the GPs (T0). GPs who were not present 
at the PTAM could be approached by the pharmacist individually for handing over the 
list. GPs were instructed to mark patients whom they considered eligible for addition of 
a statin on the basis of the new guideline with a ‘+’, and patients for whom they did 
not intend to prescribe a statin, for example because the low density lipoprotein was 
below 2.5 mmol/l (100 mg/dl) or because the patient had a statin intolerance, with a 
‘-’. They were also asked to prescribe a statin to the selected patients.
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The experimental and the control group pharmacies received a different intervention 
for the implementation of the same patient-directed service.
D ir ec t e d  a t  p h a r m a c ie s : e x p e r im e n t a l  g r o u p
Experimental pharmacists received a written educational manual in September or 
October 2006, which consisted of information about the project, step-by-step 
instructions on how to make the patient selection, suggestions for presenting the 
project to GPs and pharmacy technicians, suggestions for reminding the GPs about 
statin prescription and a flow-chart for the planning of the project. The project had a 
planned duration of 12 months. Pharmacists were also invited to an interactive 
educational meeting, which was based on the literature11,12 and on the extensive 
experience of two professional communication advisors who were well informed about 
daily practice in community pharmacies. The pharmacists were challenged by a 
communication advisor to identify and tackle potential barriers for implementation and 
to plan the steps required for the project on the basis of a predefined flowchart. Four 
reminder telephone calls were planned with each pharmacist.
D ir ec t e d  a t  p h a r m a c ie s : c o n t r o l  g r o u p
The control group pharmacies received a written educational manual in October 2006, 
which was the same as the manual for the experimental pharmacies. No further 
intervention was applied.
Measurements
Baseline characteristics of pharmacies were measured at the start of the study by 
means of a written inventory. Baseline characteristics of the selected patients and 
prescription outcomes were extracted from a national prescription database (The 
Foundation for Pharmaceutical Statistics directly gathers data from more than 1670 of 
the 1850 community pharmacies in The Netherlands. The participating pharmacies 
serve about 13.5 million people, and dispense drugs or medical aids some 140 million 
times per year. http://www.sfk.nl/algemeen/english.html) from 6 months before T0 
until T0, which could vary per pharmacy. Descriptive information regarding the 
implementation process was obtained through a written questionnaire, which was 
returned by the pharmacists at the end of the project. All pharmacists who had not 
returned the questionnaire by March 2008 were called to obtain information on the 
implementation process. Pharmacies from which no questionnaires were received and 
whose pharmacists were not reachable for telephone interview after several attempts 
were considered not to have started the project; these pharmacies were included in 
the data analyses by recording a value of zero for each step of the implementation 
process. For pharmacies that did not hand over any list with selected patients to any 
GP, T0 was calculated as the median date for T0 from the other pharmacies. Statin 
prescriptions were extracted from the national prescription database from T0 until 12 
months after T0, which could vary per pharmacy, but not later than February 2008.
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Outcomes
The primary outcome was the percentage of selected patients receiving one or more 
prescriptions of a statin in the 6 months after the GP had received the list of selected 
patients (6 months after T0). Additional outcomes, which were related to the 
implementation process, were the percentage of selected patients who were reviewed 
for an actual statin indication by a GP; the percentage of patients reviewed who had an 
actual statin indication according to the GP, the percentage of selected patients who 
received a statin 12 months after T0 and the percentage of patients with a statin 
indication according to the GP who received a statin 6 and 12 months after T0.
Sample size
We assumed that the average number of patients with antiplatelet therapy and without 
any lipid-modifying drug was 300 in each pharmacy, and that 40% of these patients 
would receive at least one prescription for a statin if their pharmacy belonged to the 
experimental group compared with 30% of the selected patients in control pharmacies. 
Accordingly, we computed that 38 clusters of pharmacies were required, based on a 
power of 0.8 to detect a significant difference (P=0.05, two sided) and an intracluster 
correlation coefficient of 0.05.
Statistical analysis
The impact of the intensive implementation programme on the implementation process 
and on the prescribing of statins was examined in a random coefficient logistic 
regression model, which took into account that patients were grouped within pharmacy 
clusters. The primary analysis was quasi intention-to-treat13. Differences in baseline 
characteristics between the control and the experimental groups of pharmacists and 
patients were tested for using unpaired t-tests and X2 tests. Data were analyzed using 
the SPSS 15.0 software package (Chicago, Illinois, USA), except the random coefficient 
logistic regression analysis, which was performed using the SAS 9.1.3 software (Cary, 
North Carolina, USA) by means of the Glimmix procedure for the dichotomous outcomes 
and the mixed procedure for the continuous outcomes.
Results
Participating pharmacies, loss to follow-up and data completeness
The flow of participants is shown in Figure 1. In total, 71 eligible pharmacies registered
for participation in the study between May and August 2006, which were grouped into
36 clusters (taking into account local collaborations). Randomization resulted in a 
control group of 34 pharmacies in 18 pharmacy clusters and an experimental group of
37 pharmacies in 18 pharmacy clusters.
Six pharmacies withdrew between September and November 2006: three of them were 
closed for ever, two had changed priorities and one pharmacy did not respond to
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repeated attempts to obtain information. As a consequence, baseline data on 
pharmacies were available for 65 pharmacies. All participating pharmacists in the 
control and the experimental groups received the educational manual. Twenty-nine of 
the 34 pharmacists in the experimental group were present in one of the educational 
meetings at the start of the project. Pharmacists had between three and nine 
telephone calls with a research assistant, the median frequency of calls was five times. 
All experimental pharmacies received the three newsletters concerning the progress of 
the project. Questionnaire data on the implementation process were obtained from 62 
pharmacies. Of the three remaining pharmacies, the actual performance of the 
implementation activities could be established by telephone interview for two 
pharmacies. Patient data at baseline and follow-up were available for 52 pharmacies: 
one pharmacy did not give authorization to the national database administrator for 
data extraction, one pharmacy had opened in October 2005 and did not have 12 
complete months of patient data before the start of the project and for 11 pharmacies 
data extraction was impossible because patient identification numbers changed during 
the project because of a switch of the pharmacy to another computer system.
Figure 1. Participant flow
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Baseline characteristics
Table 1 presents characteristics of participating pharmacies, which could influence the 
pharmacists’ care-providing function14,15. Pharmacies in both the groups were 
comparable with regard to most characteristics, except for having registered for 
participation in the study because the pharmacist perceived pressure from the health 
insurance company. In the experimental group more pharmacists participated because 
of this reason than in the control group.
Table 1. Pharmacy characteristics at baseline
Pharmacy characteristic Experimental 
group (n=34)
Control 
group (n=31)
Number of years in service managing pharmacist ± SD 14.4 ± 8.1 16.5 ± 9.3
Frequency of postgraduate training in pharmacotherapy for pharmacist:
Often (%) 6 (17.6) 8 (25.8)
Being a pharmacist trainer (%) 1 (2.9) 2 (6.5)
Attitude regarding care-providing function (continuous scale of 17-85) ± SD 69.0 ± 4.7 70.0 ± 5.9
Pharmacy technicians with specialized care-providing duties (%) 21 (61.8) 20 (64.5)
Relationship with GP: Good or very good (%) 23 (67.6) 18 (58.1)
Workload as perceived by pharmacist: High or very high (%) 11 (32.4) 9 (29.0)
How many pharmacy technicians attended classes in pharmaceutical care
in previous 12 months: More than half of technicians (%) 24 (70.6) 25 (80.6)
Pharmacy is part of chain or franchise formula (%) 23 (67.6) 20 (64.5)
Participation in study because of perception of pressure from insurance
company: Partly or completely agree (%) 9 (26.5) 2 (6.5)
GP, general practitioner; SD, standard deviation.
Baseline characteristics of selected patients were largely similar in both the groups
(Table 2).
Table 2. Characteristics of patients who used antiplatelet therapy but not a statin in the 6 months
before T0 (data from 52 pharmacies)
Patient characteristic Experimental Control group P-value
group (n=4800) (n=4462)
Male 2245 (46.8) 1911 (42.8) <0.001
Mean age in years ± SD 73.4 ± 13.3 72.1 ± 13.1 <0.001
Use of comedication
Oral blood glucose lowering drugs 464 (9.7) 416 (9.3) 0.573
Insulins 189 (3.9) 172 (3.9) 0.872
Organic nitrates 662 (13.8) 573 (12.8) 0.179
Other cardiac therapy 348 (7.3) 364 (8.2) 0.101
Diuretics 1914 (39.9) 1885 (42.2) 0.020
Beta blocking agents 1806 (37.6) 1706 (38.2) 0.546
Calcium channel blockers 1061 (22.1) 949 (21.3) 0.330
Agents acting on the Renin-Angiotensin System 1784 (37.2) 1761 (39.5) 0.023
Other antihypertensives 77 (1.6) 76 (1.7) 0.708
Chronic use of drugs that might interact with statin 575 (12.0) 517(11.6) 0.558
Data are absolute scores with the percentage between brackets, unless otherwise specified.
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Success of implementation of the intervention
The indicators for success of the implementation are shown in Table 3. In the 
experimental group, 944 patients (19.7%) from the list were reviewed by the GP versus 
482 patients (10.8%, P=0.023) in the control group. Of the patients who were reviewed, 
360 patients (38.1%) in the experimental group versus 192 patients (39.8%, P=0.393) in 
the control group had an actual indication for a statin according to the GP. There was 
no difference in the percentage of antiplatelet users to whom a statin was prescribed 
in the 6 months after T0, which was the primary outcome, between experimental and 
control groups: 276 patients (5.8%) in the experimental group versus 238 patients (5.3%, 
P=0.104) in the control group.
Six months later, 444 patients (9.9%) in the experimental group versus 376 (9.3%, 
P=0.119) in the control group had received a statin. Of the patients who had been 
reviewed and who had an indication for statins according to the GP, 52 patients (14.4%) 
received a statin prescription in the 6 months after T0 in the experimental group versus 
30 patients (15.6%, P=0.972) in the control group. Six months later, 69 of these patients 
(19.2%) in the experimental group versus 51 of these patients (26.6%, P=0.404) in the 
control group had received a statin. The observed intracluster correlation coefficient 
was 0.106 for the primary outcome.
Table 3. Success of implementation - Patient outcomes
Patient outcome Experimental group 
(patients from  
27 pharmacies 
(14 clusters))
Control group 
(patients from 
25 pharmacies 
(15 clusters))
OR (95% CI) P-value
Total number of patients reviewed by GP 
(% of selected patients)
Prescribing of statins to selected AP-users
944/4800 (19.7) 482/4462 (10.8) 4.9 (1.2-19.2) 0.023
0-6 months after T0 276/4800 (5.8) 238/4462 (5.3) 1.5 (0.9-2.6) 0.104
0-12 months after T0 444/4496 (9.9)a 376/4046 (9.3)b 1.5 (0.9-2.5) 0.119
Number of patients reviewed with statin 
indication according to GP 
Prescribing of statins to selected AP-users 
with statin indication according to GP
360/944 (38.1) 192/482 (39.8) 0.7 (0.2-1.7) 0.393
0-6 months after T0 52/360 (14.4) 30/192 (15.6) .6).3(0..0 0.972
0-12 months after T0 69/360 (19.2) 51/192 (26.6) 0.7 (0.3;1.7) 0.404
Data are absolute scores with the percentage between brackets; AP, antiplatelet therapy; CI, confidence 
interval; GP, general practitioner; OR, odds ratio.
a Data from 24 pharmacies, because follow-up was not complete for 3 pharmacies. 
b Data from 23 pharmacies, because follow-up was not complete for 2 pharmacies.
Table 4 shows process indicators for implementation success. There were no significant 
differences between the two groups for these indicators.
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Table 4. Success of implementation - Process outcomes
Process outcome Experimental 
group (n=34 
pharmacies in 
17 clusters)
Control group 
(n=31
pharmacies in 
16 clusters)
Effect size 
(95% CI)
P -value
Pharmacists who handed over at least 1 list 
to a GP at T0 (% of pharmacies)a
32 (94.1) 27 (87.1) 2.3 (0.3-19.3) 0.435
Mean number of GPs to whom a list was 
handed over b
7.8 ± 5.2 5.5 ± 5.4 2.3 (-0.3-4.9) 0.307
% of GPs in PTAM to whom a list was handed
over b
77.2 ± 50.7 60.0 ± 55.6 17.2 (-9.1-43.6) 0.260
Pharmacists who retrieved at least 1 list 
from a GP (% of pharmacies)a
16 (47.1) 17 (54.8) 0.8 (0.2-3.3) 0.786
Mean number of GPs from whom a list was 
retrievedb
2.1 ± 3.4 1.3 ± 1.4 0.8 (-0.5-2.1) 0.208
% of GPs in PTAM from whom a list was 
retrieveda
21.2 ± 35.2 15.9 ± 29.2 5.3 (-10.8-21.5) 0.441
CI, confidence interval; GP, general practitioner; PTAM, pharmacotherapy audit meeting. 
a Data are absolute scores with the percentage between brackets, effect size = odds ratio; 
b Data are mean values ± standard deviation, effect size = difference.
Discussion
Only about 5 and 10% of the selected patients received a statin in the first 6 and 12 
months, respectively after the pharmacists had handed over the lists to GPs, both in 
the control and in the experimental groups. The 10% corresponds to only 3% of all 
patients with CVD. Although the intervention in the experimental group resulted in 
almost twice as many patients being reviewed and marked as eligible by a GP for a 
statin indication compared with the control group, this did not lead to a difference in 
statin prescribing between the two groups.
The intensive implementation programme in this study resulted in moderately better 
pharmacist performance (i.e. more lists handed over to more GPs and lists retrieved 
from more GPs) and in a considerably higher percentage of patients being reviewed by 
the GP for a statin indication. Apparently, our intervention tackled the main barrier 
perceived by the pharmacists — engaging GPs in the project — reasonably well, but it 
did not overcome GPs’ barriers to actually prescribe statins. Our study was not 
designed to clarify the root causes of the prescribing barriers. Earlier studies in the UK 
and in The Netherlands indicate that organization of general practice, complexity of 
guidelines and changing guidelines, problems at the secondary-primary care interface 
and patient factors generally seem to be the most important barriers to prescribe 
statins to patients at high-cardiovascular risk16,17. Cabana et al.18 identified seven 
general categories of barriers to physician adherence to practice guidelines in relation 
to behaviour change. Of these seven categories, lack of awareness, lack of familiarity, 
lack of agreement with the guideline on cardiovascular risk management and lack of 
outcome expectancy were not likely to be applicable, especially for the GPs who 
reviewed the lists with selected patients. A lack of self efficacy, lack of motivation or
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inertia of earlier practice and external barriers, like patient factors, lack of time or 
organizational constraints could have contributed to the limited prescribing of statins in 
this study. An earlier audit in 95 practices in The Netherlands supports this assumption, 
except for the finding that most GPs had positive self-efficacy expectations19. The 
relationship between pharmacists and GPs was rated good or very good by less than two 
thirds of the pharmacists. Possibly, this might also have played a role in the limited 
cooperation of GPs in this study. Next, a television broadcast in March 2007, which was 
very negative about preventive use of statins, may have discouraged one or more GPs 
from discussing the need for prescribing a statin with their patients. It remains unclear 
to which extent the observed statin prescriptions were a direct consequence of this 
study, or to which extent it resulted from other programmes for improving statin 
prescribing. Whether additional interventions directed at GPs, for example an 
educational meeting, an organizational intervention or additional remuneration on top 
of the fixed fee per prescription can overcome the prescribing barriers for GPs, is a 
subject for further research.
This study has strengths and limitations. Among the strengths were the randomized 
design, large sample size and low drop-out rates for the pharmacies in addition to the 
high degree of validity for the prescription data extracted from the national 
prescription database. The use of a clinical guideline by the Dutch College of General 
Practitioners with clear recommendations with a solid scientific foundation was a 
strength as well20. A limitation was that antiplatelet therapy, which was used for 
identification of patients who were likely to have CVD in this study, is not a perfect 
tool. Only about two thirds of the antiplatelet users in general practice have a 
recorded diagnosis of CVD2 and the GPs who reviewed the selected patients in this 
study assessed that about 40% of them had a statin indication. The ineligibility for a 
statin could only explain a small part of the ultimately limited statin prescription, 
however, as only 15% of the patients with a statin indication according to the GP 
received a statin after 6 months.
Of the 211 pharmacies invited for participation, only 71 actually registered for our 
study. Unfortunately, we were not able to determine why pharmacies chose not to 
participate or whether they were comparable with the pharmacies that were enrolled 
in the study. It is therefore unclear to which extent voluntary participation may have 
lead to bias. Another limitation comprises the substantial number of pharmacies for 
which no patient data could be obtained. The performance of those pharmacies was 
comparable with the pharmacies of which we did have patient data. Therefore, we do 
not expect that the outcomes were biased as a result of this limitation.
Our findings indicate that pharmacists can play a significant role in primary care in the 
identification of patients at high-cardiovascular risk who are yet to receive optimal 
preventive pharmacotherapy and that an intensive implementation programme can 
improve the performance of pharmacists in their cooperation with GPs. Future studies
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should investigate how the reach of the implementation programme can be extended to 
actually improving statin prescribing, either by extending the implementation 
programme to the GPs or by extending current possibilities of pharmacists to prescribe 
statins themselves (of course within the framework of a formal agreement with the 
local GPs).
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Abstract
Background: As a result of the previous part of this trial, many patients with 
cardiovascular disease were expected to receive a statin for the first time. In order to 
provide these patients with comprehensive information on statins, as recommended by 
professional guidance, education at first and second dispensing of statins had to be 
implemented. This study was designed to assess the effectiveness of an intensive 
implementation programme targeted at pharmacy project assistants on the frequency 
of providing education at first dispensing (EAFD) and education at second dispensing 
(EASD) of statins in community pharmacies.
Methods: The participating community pharmacies were clustered on the basis of local 
collaboration, were numbered by a research assistant and subsequently an independent 
statistician performed a block randomization, in which the cluster size (number of 
pharmacies in each cluster) was balanced. The pharmacies in the control group 
received a written manual on the implementation of EAFD and EASD; the pharmacies in 
the intervention group received intensive support for the implementation. The impact 
of the intensive implementation programme on the implementation process and on the 
primary outcomes was examined in a random coefficient logistic regression model, 
which took into account that patients were grouped within pharmacy clusters.
Results: Of the 37 pharmacies in the intervention group, 17 pharmacies (50%) provided 
EAFD and 12 pharmacies (35.3%) provided EASD compared to 14 pharmacies (45.2%, 
P=0.715) and 12 pharmacies (38.7%, P=0.899), respectively, of the 34 pharmacies in the 
control group. In the intervention group a total of 72 of 469 new statin users (15.4%) 
received education and 49 of 393 patients with a second statin prescription (12.5%) 
compared to 78 of 402 new users (19.4%, P=0.944) and 35 of 342 patients with a second 
prescription (10.2%, P=0.579) in the control group.
Conclusion: The intensive implementation programme did not increase the frequency of 
providing EAFD and EASD of statins in community pharmacies.
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Background
In October 2006 we started a trial in order to improve the prescribing of statins for 
patients with CVD in general practice1. As a result of this trial, many patients with CVD 
were expected to receive a statin for the first time. In order to provide these patients 
with comprehensive information on statins, as recommended by professional guidance, 
education at first and second dispensing of statins had to be implemented.
Patient education is a basic element of community pharmacy practice according to the 
Dutch Pharmacy Standard2 and according to several international guidelines3. Such 
patient education is required from a legal and ethical perspective, and it is also 
recommended to ensure that patients understand how to use medication safely and 
effectively3. At the time this study was designed, providing education at first and 
second dispensing of medication in community pharmacies was also expected to 
improve medication adherence and persistence in The Netherlands, although evidence 
for that was scarce. Poor medication adherence or even total discontinuation of statin 
therapy for secondary prevention is highly prevalent and an important problem because 
it increases mortality and cardiovascular events4,5. Use of statins for secondary 
prevention rapidly decreases in the first months, with a gradually smaller decrease on 
the longer term6. Between 60% and 86% of the patients still use a statin one year after 
their first cardiovascular event7,8, and between 44% and 80% after two or more 
years6,9-11. So, enhancing adherence and persistence with statin therapy is important 
for optimal secondary prevention of CVD for the patients in our trial.
Patient education is not provided by all pharmacies to all patients at each dispensing. A 
review from 36 studies in the USA, Europe, Australia and Canada shows that counseling 
was provided by 50% to 100% of the pharmacies to 8% to 80% of the patients3. The 
barriers for implementing patient education in community pharmacy which we 
identified from the first author’s own experience as a pharmacist, from pharmacists’ 
reported barriers and facilitators in a previous trial in which we implemented another 
pharmaceutical care service12 and from the literature13,14 were: A) Organizational: 
making time for introducing patient education to the pharmacy technicians and for 
educating them; lack of time and space for providing patient education; patients’ 
privacy; the availability of protocols for patient education; lack of documentation of 
patient education that was provided; lack of reimbursement; involvement of pharmacy 
technicians in the implementation process; B) With regard to the individual 
professionals: knowledge and skills of pharmacists and pharmacy technicians; attitude 
towards patient education; C) Factors concerning the social context: patient 
indifference.
Successful implementation of patient education requires a comprehensive approach, 
which targets relevant barriers and facilitators to change in a specific setting15. 
Unfortunately, an evidence-based strategy to translate identified barriers to a tailor- 
made implementation intervention is still lacking16. So, after having identified the
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potential barriers for the implementation of patient education, we used common sense 
to design the intensive implementation intervention, thus following the planning model 
described by Grol and Wensing17. Our intensive multifaceted implementation 
programme was directed at pharmacists and at pharmacy technicians who were 
appointed as project assistant. This programme consisted of an educational manual, 
two interactive educational meetings, reminder and feedback telephone calls and 
reminder newsletters.
The aim of the present study was to test the hypothesis that the intensive 
implementation programme would increase the frequency of patient education 
provided at first and second dispensing of statins in community pharmacies.
Methods
A cluster randomized trial was conducted between September 2006 and February 2008. 
The medical ethical committee Arnhem-Nijmegen gave approval for this trial. The trial 
consisted of two parts: in the first part, which is described elsewhere1, prescribing of 
statins for secondary prevention of cardiovascular disease was targeted. In the second 
part, which is described here, the focus was on patient education at the moment 
patients presented a statin prescription in a community pharmacy for the first or 
second time.
Participants
Community pharmacies were recruited through a mailing to all 211 pharmacies in the 
South of The Netherlands in April 2006. Participation was voluntary, though encouraged 
by one of the two major health insurance companies in this part of The Netherlands: 
pharmacies participating in this study were exempted from presenting an annual plan 
and from reporting of patient care activities. There was no financial incentive for 
participation in the project other than the usual dispensing fee per prescription. 
Patients who were selected in the first part of the trial (which were patients who 
already used antiplatelet medication but not a statin) and who received a first or a 
second statin prescription were eligible for education by a pharmacist or pharmacy 
technician.
Randomization
In order to ensure that pharmacies in the control group would not be influenced by the 
intensive implementation programme, all pharmacies that cooperated with the same 
GPs or that had local collaboration with another pharmacy in the vicinity were grouped 
in a cluster of pharmacies. The clustered pharmacies were numbered by a research 
assistant. An independent statistician performed a block randomization, in which the 
cluster size (number of pharmacies in each cluster) was balanced.
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Interventions
In all pharmacies, both in the control group and in the experimental group, pharmacists 
and pharmacy technicians were instructed to provide education at first dispensing 
(EAFD) and education at second dispensing (EASD) to new statin users, guided by the 
same protocols for EAFD and EASD. The difference between the two groups consisted of 
the way they were supported with the implementation of EAFD and EASD.
D ir ec t e d  a t  p a t ie n t s
The protocol for EAFD stated that the pharmacist or pharmacy technician should read 
out loud the patient label including information on the name, strength and use of the 
statin, and should explain the importance of long-term use of the statin to each 
patient. If the patient appeared to be interested and if there was enough time, one or 
more of the following issues could be discussed as well: indication of the statin; how it 
works; side effects; what to do when a dose intake was missed; interactions; and if 
everything was clear to the patient or whether he or she had any more questions. We 
advised the pharmacies not to give too much information at first dispensing, because 
patients generally receive a lot of information from the physician at the visit in which 
they receive their first statin prescription. The information provided in the pharmacy 
should be sufficient to motivate the patient to use the statin at least until the second 
dispensing, which is the moment at which the patient’s experiences with using the 
medication are discussed and more information can be provided.
According to the protocol, EASD (which is normally two weeks after first dispensing in 
The Netherlands) started with the question how the patient had experienced statin use. 
When the patient had a positive experience, pharmacists and pharmacy technicians 
were instructed to emphasize the importance of long-term use once more and to 
mention the possibility to ask questions about medications in the pharmacy. When the 
patient expressed a negative experience, pharmacists and pharmacy technicians were 
instructed to find out whether the patient had any specific questions or problems and 
whether they could help the patient with that.
D ir ec t e d  a t  p h a r m a c ie s : e x p e r im e n t a l  g r o u p
Experimental pharmacies received a written educational manual in September or 
October 2006, which consisted of information about the project; step-by-step 
instructions for carrying out the project; protocols for EAFD and EASD, an explanation 
of these protocols and examples of possible situations at second dispensing for the 
pharmacy technicians to practice with; and a flow-chart for the planning of the 
project. The project had a planned duration of 12 months. Pharmacists and pharmacy 
technicians who were appointed as project assistant were also invited to an interactive 
educational meeting, which was based on the literature14 and on the extensive 
experience of two professional communication advisors who were well-informed about 
daily practice in community pharmacies. After an explanation of the project (what, 
why, how, by whom, when) by one of the researchers (CvdS), pharmacists and project
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assistants split up. Pharmacists mainly discussed the first part of the trial; the project 
assistants discussed their experience with EAFD and EASD, and expectations with regard 
to this project under the guidance of two research assistants and guided by a 
questionnaire. In a second interactive educational meeting, project assistants were 
challenged by a communication advisor to identify facilitators of implementation and 
to identify and tackle potential barriers for implementation with regard to the content 
of the protocols; organization of patient education; and knowledge and motivation of 
the pharmacy technicians. In the four reminder telephone calls which were planned 
with each pharmacist for the first part of the trial, the project assistants were also 
interviewed and supported with the implementation of patient education.
D ir ec t e d  a t  p h a r m a c ie s : c o n t r o l  g r o u p
The control group pharmacies received a written educational manual in October 2006, 
which was the same as the manual for the experimental pharmacies. No further 
intervention was applied.
Measurements
For each time education was given at first and second dispensing, the pharmacist or 
pharmacy technician marked the items which were discussed on a written checklist. 
“EAFD as recommended” included both having read out loud the patient label with 
information on the name, strength and use of the statin; and having explained the 
importance of long-term use. Statin prescriptions for patients who received at least one 
antiplatelet drug as well as sex, age and prescriptions for other cardiovascular drugs or 
drugs with a statin interaction were extracted from a national prescription database, 
which consists of all dispensing data from more than 1,670 of the 1,850 community 
pharmacies in the Netherlands. The pharmacies which provide data to this database 
serve about 13.5 million people, and dispense drugs or medical aids some 140 million 
times per year (more information at http://www.sfk.nl/algemeen/english.html). A 
statin prescription was considered a first prescription if there were no statin 
prescriptions in the database in the six months before the pharmacy started the first 
part of the trial. Follow-up data on statin use were available until February 2008. 
Pharmacy characteristics were measured at the start of the study by means of a written 
inventory. Barriers and facilitators with regard to the implementation process in the 
experimental pharmacies were collected by means of the telephone interviews which 
were part of the intensive implementation programme.
Outcomes
The primary outcome of the study was the percentage of patients with a first 
prescription for a statin who received EAFD. The secondary outcome of the study was 
the percentage of patients with a second prescription for a statin who received EASD.
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Additional outcomes were perceived barriers and facilitators to implementation in the 
intervention group and the effect of EAFD and EASD on persistence with statin therapy.
Sample size
Because this was the sequel of a trial which was designed to enhance statin prescribing 
for patients with cardiovascular disease, the sample size needed was not calculated for 
the primary outcome of this study, but for the primary outcome of the first part of the 
trial. We planned to include 7980 patients from 76 pharmacies.
Statistical analysis
The impact of the intensive implementation programme on the implementation process 
and on the primary outcomes was examined in a random coefficient logistic regression 
model, which took into account that patients were grouped within pharmacy clusters. 
The primary analysis was quasi intention-to-treat18 and involved all patients of whom 
statin dispensing data were known. P-values of 0.05 or less were considered significant. 
Determinants for providing EAFD were tested for using unpaired t-tests and X2 tests. 
Data were analyzed using the SPSS 16.0 software package, except the random 
coefficient logistic regression analysis, which was performed using the SAS 9.1.3 
software by means of the Glimmix procedure.
Results
Participating pharmacies, loss to follow-up and data completeness 
The flow of participants throughout the study is shown in Figure 1. In total, 71 eligible 
pharmacies registered for participation in the study between May and August 2006, 
which were grouped into 36 clusters (taking into account local collaborations). 
Randomization resulted in a control group of 34 pharmacies in 18 pharmacy clusters 
and an experimental group of 37 pharmacies in 18 pharmacy clusters.
Six pharmacies withdrew between September and November 2006: three of them were 
closed for ever; two had changed priorities; and one pharmacy did not respond to 
repeated attempts to obtain information. Patient data at baseline and follow-up were 
available for 52 pharmacies: one pharmacy did not give authorization to the national 
database administrator for data extraction; one pharmacy had opened in October 2005 
and did not have 12 complete months of patient data before the start of the project, 
which was required for the first part of the trial; and for 11 pharmacies data extraction 
was impossible because patient identification numbers changed during the project due 
to a switch of the pharmacy to another computer system.
In the 52 pharmacies for which patient data were available, 871 of the selected 
patients were eligible for EAFD since they received a first statin prescription within 12 
months after the start of the project and 735 patients also received a second statin 
prescription, which made them eligible for EASD as well.
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Figure 1. Participant flow
Success of the implementation
The indicators for success of the implementation are shown in Table 1. In the control 
group, 14 pharmacies (45.2%) did provide EAFD and 12 pharmacies (38.7%) did provide 
EASD, respectively, versus 17 pharmacies (50.0%, P=0.715) and 12 pharmacies (35.3%, 
P=0.899), respectively, in the experimental group. There were no differences between 
the two groups in the primary or in the secondary outcome: 78 patients (19.4%) with a 
first statin prescription received EAFD and 35 patients (10.2%) received EASD in the
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control group, versus 72 patients (15.5%, P=0.944) and 49 patients (12.5%, P=0.579) in 
the experimental group. Also, the percentage of new users who received EAFD in the 
pharmacies who did implement EAFD was similar in both groups. The pharmacy which 
performed best, offered EAFD and EASD to 15 of the 19 patients (78.9%) who received a 
first statin prescription after the pharmacy had started providing EAFD. The Intracluster 
correlation coefficient (ICC) for the primary outcome was 0.347. In the pharmacies 
which did provide EASD to at least one patient, a higher percentage of the new statin 
users received EASD in the experimental group, but this difference did not reach 
significance: 28.2% versus 17.1% in the control group (P=0.172) in the multilevel 
analysis.
Table 1. Indicators for success of implementation
Experimental 
group________
Control
group
OR (95% CI) P-value
Frequency of EAFD offered (% of first 
prescriptions)a 
Number of pharmacies which offered EAFD (%) 
Frequency of EAFD offered in the pharmacies 
which performed EAFD (% of first 
prescriptions)b 
Frequency of EASD offered (% of second 
prescriptions)a 
Number of pharmacies which offered EASD (%) 
Frequency of EASD offered in the pharmacies 
which did perform EASD (% of second 
prescriptions)c
72/469 (15.4) 78/402 (19.4) 0.96 (0.31;3.01) 0.944
17/34 (50.0) 14/31 (45.2) 1.24 (0.38;4.00) 0.715 
72/252 (28.6) 78/257 (30.4) 1.08 (0.51 ;2.29) 0.845
49/393 (12.5) 35/342 (10.2) 1.41 (0.42;4.78) 0.579
12/34 (35.3) 12/31 (38.7) 0.93 (0.27;3.20) 0.899 
49/174 (28.2) 35/205 (17.1) 1.85 (0.76;4.50) 0.172
EAFD, education at first dispensing; EASD, education at second dispensing
a Data from the pharmacies of which the total number of first statin prescriptions was known, which 
were 25 pharmacies in the control group and 27 pharmacies in the experimental group. 
b Data from the pharmacies which did perform EAFD and of which the total number of first statin 
prescriptions was known: 12 pharmacies in the control group and 13 pharmacies in the experimental 
group.
c Data from the pharmacies which did perform EASD and of which the total number of second statin 
prescriptions was known: 10 pharmacies in the control group and 10 pharmacies in the experimental 
group.
Table 2 shows the integrity of education in subjects who received education at first 
dispensing. The patient label was read out loud at first dispensing more frequently in 
the experimental group than in the control group (86.1% versus 69.2%, P=0.017), and 
more patients received EAFD on the indication for the statin in the experimental group 
(77.8% versus 59.0%, P=0.016).
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Table 2. Integrity of education in subjects who received education at first dispensing
Experimental Control group P-value
group (N=72) (N=78)
Patient himself/herself fetched medication and was 49 (68.1) 47 (60.3) 0.323
interested
Patient label read out loud a;b 62 (86.1) 54 (69.2) 0.017
Importance of long-term use a 53 (73.6) 47 (60.3) 0.098
Indication of the statin 56 (77.8) 46 (59.0) 0.016
How statin works 44 (61.1) 45 (57.7) 0.661
Side effects 47 (65.3) 48 (61.5) 0.636
What to do when a dose intake is missed 20 (27.8) 24 (30.8) 0.577
Interactions 20 (27.8) 27 (34.6) 0.352
Contact for more information 33 (45.8) 36 (46.2) 0.931
At least one of these 65 (90.3) 55 (70.5) 0.006
Both subjects which were recommended in protocol EAFD 51 (70.8) 47 (60.3) 0.179
Data are absolute frequencies, with the percentage between brackets. EAFD, education at first 
dispensing
a Recommended in the protocol for education at first dispensing. 
b The patient label includes information on the name, strength and use of the statin.
In Table 3 the pharmacy characteristics related to education at first dispensing are 
shown. None of the pharmacy characteristics was significantly related to providing 
EAFD.
Table 3. Characteristics of pharmacies related to education at first dispensing
Pharmacies which 
did educate 
patients at first 
dispensing (N=31)
Pharmacies which 
did not educate 
patients at first 
dispensing (N=34)
P-value
Number of years in service pharmacista 16.5 ± 9.0 14.5 ± 8.5 0.382
Frequency of postgraduate training in 
pharmacotherapy for pharmacist: Regularly or Often
28 (90.3) 32 (94.1) 0.566
Attitude regarding care-providing function (continuous 
scale of 16-80)a;b
66.2 ± 6.6 66.3 ± 6.6 0.969
Pharmacy technicians with specialized care-providing 
duties
18 (58.1) 23 (67.6) 0.424
Relationship with GP: Good or very good 22 (71.0) 19 (55.9) 0.208
Workload as perceived by pharmacist: High or very 
high
10 (32.3) 10 (29.4) 0.804
Pharmacy is part of chain or franchise formula 21 (67.7) 22 (64.7) 0.796
Participation in study because of perception of 
pressure from insurance company: Partly or 
completely agree
5 (16.1) 6 (17.6) 0.870
Number of first statin prescriptions within 6 months of 
start of the project
11.7 ± 8.0 7.9 ± 7.3 0.082
Team was used to providing education at first 
dispensing of (some types of) medication
30 (96.8) 30 (88.2) 0.197
Data are absolute scores (% in brackets) unless otherwise specified. GP, general practitioner 
a Data are mean scores ± standard deviation
b Attitude was measured, using the statements which are described in the Appendix (page 75).
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Barriers and facilitators
The main barrier reported by the project assistants in the experimental group was that 
the pharmacist chose (either explicitly or implicitly) not to start with EAFD and EASD: 
In three pharmacies the project had discontinued completely, in five pharmacies the 
pharmacist did not want to start before the general practitioners had reviewed and 
returned the list with selected patients on which they had marked the patients with a 
statin indication, which was late or did not happen at all. In five other pharmacies, the 
pharmacist did not take much initiative to retrieve the lists or to start with EAFD and 
EASD, according to the project assistants. The project assistant and other pharmacy 
technicians were discouraged by that. Other barriers with regard to the 
implementation were insufficient staff (5x); negative reactions from patients (4x); lack 
of routine because of the limited number of new statin users (2x); lack of experience 
with EASD (2x); forgetting to fill in the checklist sometimes (2x); other priorities in the 
pharmacy (1x); and difficulties with opening a conversation at the moment of second 
dispensing (1x).
Perceived facilitators were enthusiastic pharmacy technicians (8x); pharmacy 
technicians who were used to providing EAFD and/or EASD (7x); positive reactions of 
patients (5x); project materials (2x); computer reminder at the moment of first or 
second dispensing (2x); patients were informed before they visited the pharmacy by a 
general practitioner or by means of a letter (2x); pharmacist gave feedback to 
pharmacy technicians (1x); materials on a visible place (1x); EAFD and EASD fitted well 
into the regular work system (1x). Pharmacies which performed best in this study did 
not report obviously different barriers or facilitators than pharmacies which did not 
perform well.
Effect of education at first and second dispensing
Table 4 shows the use of statins related to whether patients received education at first 
or second dispensing as recommended by the study protocol. In the group of patients 
who did receive EAFD as recommended, significantly more patients received a second 
statin prescription: 93.9% versus 83.2% in the group of patients who did not receive 
EAFD as recommended (P=0.028). The difference was no longer significant after 6 
months: 80.7% of the patients who did receive EAFD as recommended used the statin 
for at least 6 months versus 77.0% of the patients who did not receive EAFD as 
recommended (P=0.867). A non-significant difference was also found between patients 
who did versus patients who did not receive EASD: 91.2% of the patients in the first 
group still used the statin after 6 months, versus 83.2% of the patients in the second 
group (P=0.216).
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Table 4. Use of statins related to receiving education at dispensing as recommended
Yes No P-value
Number of patients who received a second statin 
prescription (%) related to whether they had received EAFD 
as recommended (yes/no)
92/98 (93.9) 643/773 (83.2) 0.028
Number of patients who still used a statin 6 months after 
first dispensing (%) related to whether they had received 
EAFD as recommended (yes/no)a
71/88 (80.7) 435/565 (77.0) 0.867
Number of patients with a second statin prescription who 
still used a statin 6 months after first dispensing (%) 
related to whether they had received EASD (yes/no)a
73/80 (91.2) 421/506 (83.2) 0.216
a Data from patients with at least 6 months follow up after first dispensing.
Discussion
Only half of all pharmacies provided EAFD to at least one patient and in the pharmacies 
which did, less than one third of the patients received EAFD on average. Apparently, 
the intensive implementation programme was not able to overcome the main barriers 
or to enhance factors needed for providing EAFD and EASD to new statin users. 
Pharmacies in the intervention group did not provide more education to patients at 
first or second dispensing of statins compared to the pharmacies in the control group. A 
review of 36 studies on patient education on medication3 indicated that 29-87% of 
pharmacists or other pharmacy staff counseled 40-69% of all patients with a 
prescription for new medication. So, the finding that half of the pharmacies provided 
patient education in our study is similar to previous findings, but the percentage of new 
statin users receiving EAFD in our study was low compared to other research.
None of the characteristics which were related to the pharmacy’s care providing 
function in previous studies12,19 or of the other factors we investigated was related to 
providing EAFD. It is remarkable that being used to providing EAFD did not influence 
the frequency of EAFD in this study. For patient education on the negative effects of 
benzodiazepines, Ten Wolde et al.20 reported that pharmacists’ intention to provide 
education was higher if they expected more positive outcomes and if they experienced 
stronger social pressure to provide education. It is very well possible that pharmacists’ 
intention to provide EAFD and EASD in our study may have influenced the 
implementation. A substantial number of pharmacies started late or not at all, with 
EAFD and EASD, because pharmacists waited for GPs to have checked the selected 
patients for an actual statin indication. Possibly, some pharmacists were not only 
rather passive in retrieving the lists from general practitioners, but in managing the 
team of pharmacy technicians as well. Whether the intensive implementation 
programme should have been directed not mainly at the project assistants, but also 
more at the pharmacists, will be a topic for further research.
In the pharmacies which started late with EAFD and EASD, patients might have received 
a statin before the pharmacy had started providing education. If we had only taken into
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account the patients who received a statin after the pharmacies had started with EAFD, 
than we would have found that more than one third of them did receive EAFD, which is 
still a low percentage. The low number of first statin prescriptions may also have 
contributed to the limited provision of EAFD and EASD in both groups, because enough 
exposure is needed for pharmacy technicians to become skilled in providing a new 
service. However, in most pharmacies the pharmacy technicians were already used to 
providing patient education at first dispensing of (some types of) medication. Finally, 
the measurement of the provision of EAFD and EASD by means of point of care 
checklists that were filled in manually may have caused underreporting of EAFD and 
EASD.
Although the intensive implementation programme did not succeed in a better 
implementation of EAFD and EASD, it did have some effect on two elements of EAFD 
and EASD. Pharmacies in the experimental group appear to have chosen to focus on 
three aspects of EAFD, even if the patient did not fetch the medication 
himself/herself: read out loud the patient label with information about correct use; the 
indication for the statin; and the importance of its long-term use. This largely complies 
with the recommendation in the protocol for EAFD, which was also a subject in the 
second interactive educational meeting as a part of the intensive implementation 
strategy. Additionally, in the pharmacies which implemented EAFD and EASD, 
significantly more patients in the experimental group received EASD compared to 
patients in the control group. Experimental pharmacies provided EASD as frequently as 
they provided EAFD.
At the time this study was designed, providing EAFD and EASD was expected to improve 
medication adherence and persistence, even though the evidence for that was still 
lacking. This study was not designed to examine the effect of EAFD and EASD on statin 
persistence, so the results - which indicate a possible positive effect of EAFD on the 
short term - should be interpreted with caution. Possibly, there were differences in the 
quality of patient education between the control group and the experimental group, or 
differences in the education GPs had already given to their patients which could have 
attributed to the improved adherence in the experimental group. About 15% of the new 
statin users did not receive a second prescription, which indicates that use of statins 
rapidly decreases in an early stage, with a gradually smaller decrease on the longer 
term. This is in line with previous research6. In the meanwhile, several studies have 
been performed to investigate the effect of patient education on patients’ adherence 
and persistence with statins. In general, interventions for improving adherence with 
chronic medication that have been shown to be effective are complex and do not lead 
to large improvements in adherence21. Studies which were published more recently 
have shown that simple interventions have not been able to increase patients’ 
adherence with statins22 or with other medicines for chronic use, among others lipid 
modifying agents23. A more extensive form of patient education, which existed of brief
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counselling by a physician followed by patient education mailings, has been shown to 
increase adherence with statins after four months24. Another intensive programme has 
been shown to improve statin taking for at least one and a half year after cessation of 
the programme25, whereas another intensive programme has been shown only to 
improve lipid levels in new statin users at three and six months after the start of the 
programme, but not after one year26. Note that all residents in the Netherlands have an 
obligatory health insurance, which covers most medication. At the time of the study, 
there was no policy excess yet. So, out-of-pocket cost will not have hampered 
medication adherence in this study.
The randomized design was a strength of our study, although the statistical power was 
not focused on the outcomes reported here. As the pharmacies did not include the 
expected number of new statin users the number of patients included in this second 
part of the study remained low. It is possible that the intensive implementation 
programme would have been more effective if more GPs would have cooperated 
actively in the first part of the trial and if more patients would have received a first 
statin prescription. Another weakness included the manual registration of EAFD and 
EASD by the pharmacy technicians. Occasionally they may have forgotten to complete 
the checklists, which may have led to underreporting of EAFD and EASD. On the other 
hand, manual registration at each first or second dispensing had the advantage that it 
was an objective measure and that recall bias could be avoided. By only using the 
checklists, we did not have any information on the quality of education provided.
Conclusion
The intensive implementation programme has not been able to increase the frequency 
of patient education provided at first and second dispensing of statins in community 
pharmacies, but it did accomplish that more patients received EASD in the pharmacies 
that implemented EASD. It remains unclear which factors contribute to successful 
implementation of EAFD and EASD. Although this study was not designed to investigate 
the effect of EAFD and EASD on statin adherence and persistence, the results indicate a 
possible positive effect on short term.
Because patient education is a basic element of pharmaceutical care, more efforts are 
required to implement EAFD and EASD on a large scale. Also, more research is needed 
to evaluate which factors influence their implementation and to develop a more 
effective implementation strategy. The effect of EAFD and EASD on patients’ 
persistence with medication should be evaluated as well.
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Appendix
Attitude was measured using the construct developed by Muijrers et al.19. The 
statements could be responded to with completely agree, partly agree, neutral, partly 
disagree or completely disagree.
1. Pharmacists are the major medication experts in primary care.
2. The pharmacist should play a very important role in the care for patients who are 
actively using drugs.
3. Pharmacists greatly influence the use of medication.
4. The pharmacist should play a very important role in the drug prescription policy of 
the general practitioner.
5. Being a pharmacist, I hardly have any influence on the drug prescription policies of 
the general practitioners in my area of care.
6. To a major extent, the pharmacist is co-responsible for the drug therapy of his 
pharmacy’s patients.
7. If a general practitioner is not sure about which drug therapy is most suitable for a 
given patient, the general practitioner should contact the pharmacist for advice.
8. When trying to make agreements within the PTAM group, the input of the 
pharmacist is essential.
9. The pharmacist should contribute to the PTAM agenda by supplying information 
about the prescription patterns observed in his/her pharmacy.
10. It is the task of the pharmacist to provide feedback to general practitioners with 
regard to their prescription figures.
11. The only responsibility of the pharmacist is to distribute drugs (i.e. providing the 
drug plus a brief instruction to the patient on how to use it, as well as monitoring 
potentially harmful interactions with other drugs).
12. The pharmacist should be aware of all the diagnosed conditions of a given patient 
which may affect medication response.
13. The pharmacist should be allowed to provide a pharmacotherapeutic substitute 
(i.e. an analogous drug, rather than the prescribed drug, is provided to the 
patient).
14. The pharmacist should be authorized to provide repeat-medication independently 
of the general practitioner.
15. It is the responsibility of the pharmacist to document undesirable prescription 
patterns of general practitioners.
16. In her/his role as medication expert, the pharmacist is responsible for the 
consequences of providing irrational drug therapy.
The statement “The pharmacist should be allowed to provide a generic drug instead of 
a prescribed specialty drug” was omitted from this construct, because this is everyday 
practice in The Netherlands.
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Abstract
Background: Uncontrolled hypertension despite treatment is highly prevalent among 
hypertension patients. Electronic monitoring of medication adherence has been proven 
to be effective in improving blood pressure. The aim of the study was to compare the 
effectiveness of intensive support for implementation of this tool in community 
pharmacies with minimal implementation support.
Methods: In a cluster randomized trial, 25 control pharmacies received a manual and 32 
experimental pharmacies received intensive support to enhance implementation of 
electronic monitoring. Primary outcome: the number of patients included for electronic 
monitoring. Secondary outcomes included mean change in systolic blood pressure (SBP) 
and percentage of patients with adequate SBP control.
Results: The experimental group yielded consistently higher scores on all the steps of 
the implementation process than the control group, but none of these differences were 
significant. The mean number of patients per pharmacy included for electronic 
monitoring in a 3-9-months period was 1.6 in the experimental group vs. 1.0 in the 
control group (difference=0.7, 95% confidence interval=-0.4; 1.7).
The following patient outcomes were pooled because there were no differences 
between the experimental and the control group. Mean change of SBP/diastolic blood 
pressure (DBP) was -12 and -6 mm Hg, respectively, SBP dropped <140 mm Hg in 20.9% 
of all patients. In 13.6% of all patients control of SBP was achieved without treatment 
intensification.
Conclusion: The intensive implementation programme enhanced pharmacist 
performance, but appeared insufficient to overcome all problems with the 
implementation of electronic monitoring. The major restrictive factors concerned 
general practitioner (GP) involvement and the identification of eligible patients.
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Introduction
Implementation of innovations into routine healthcare delivery does not usually happen 
easily or completely1. Furthermore, the effectiveness of a clinical intervention can be 
reduced after large-scale implementation. Many professional-directed programmes 
have been studied to enhance the implementation of various innovations, with a 
median absolute risk difference of about 5% and a large effect range for all of these 
programmes2-6. Successful implementation generally requires a comprehensive 
approach, in which barriers and facilitators to change in a specific setting are 
targeted7. It is not yet clear, however, when and to which extent multifaceted 
interventions targeted at health-care providers are more effective than single 
interventions.
Electronic monitoring of patient adherence with antihypertensive drugs is an innovation 
that may be worth implementing. Hypertension is an important risk factor for 
cardiovascular disease, the main cause of mortality in developed countries8. According 
to a systematic review which reported data from 35 countries, mean prevalence of 
hypertension in developed countries in patients aged 35-64 years was about 40% among 
men and about 30% among women. On average only one third of the antihypertensive 
patients had a blood pressure <140/90 mm Hg9. It is important that interventions are 
simple and feasible in (busy) clinical practice10. In previous studies, electronic 
monitoring of adherence to antihypertensive drug treatment resulted in improvement 
of blood pressure11,12 with a reduced need for treatment intensification13. Because of 
these effects and the simplicity of the method, electronic monitoring qualifies for 
larger-scale implementation in routine healthcare delivery14.
The aim of the present study was to test the hypothesis that an intensive, multifaceted 
programme for pharmacists, tailored to a setting in which community pharmacists 
cooperate with general practitioners (GPs), improves the implementation of an 
electronic adherence support intervention more than sending an educational manual to 
pharmacists, which currently is a widely used method for dissemination of 
pharmaceutical care interventions.
Methods
Participants
Community pharmacies in the South of The Netherlands were recruited through a 
mailing to all 158 pharmacies in this region in April 2006. Participation was voluntary, 
though encouraged by one of the two major health insurance companies in this part of 
The Netherlands: pharmacies participating in this study were exempted from 
presenting their annual plan and from reporting of patient care activities. There was no 
financial incentive for participation in the project other than the usual dispensing fee 
per prescription. The average community pharmacy in The Netherlands served about 
8,600 patients, with about 87,000 prescriptions in 200715. About 35% of the Dutch
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pharmacies are owned by a pharmacy chain16 and mail-order pharmacy is still in its 
infancy.
The participating pharmacists were instructed to invite at least one GP with whom they 
had professional contact regularly, to cooperate in the study. The GPs were asked to 
refer patients to the pharmacist for participation in the study if patients: were 18 years 
old or older; had a diagnosis of hypertension; used at least one antihypertensive drug; 
had a systolic blood pressure (SBP) between 150 and 180 mm Hg; and had an indication 
for dose intensification of the antihypertensive medication. Pharmacists were 
instructed at the start of the study (April 2007) to aim at including 10 patients before 
1st January 2008.
Randomization
In about 80% of the situations more than one pharmacy cooperated regularly with 
another pharmacy that participated in the study and/or they cooperated with the same 
GPs. If one pharmacy would have a very good cooperation with a GP in this project, and 
this GP would identify and refer many patients, another pharmacy could take 
advantage of this, regardless of its own activities. In order to ensure that pharmacies in 
the control group would not benefit by the intensive implementation programme, all 
pharmacies which cooperated with the same GPs or which had local collaboration with 
another pharmacy in the vicinity were grouped in a cluster of pharmacies. The 
clustered pharmacies were numbered by a research assistant. An independent 
statistician performed a block randomization, in which the cluster size (number of 
pharmacies in each cluster) was balanced.
Interventions
A d h e r e n c e  su p p o r t  d ir e c t e d  a t  p a t ie n t s
In all pharmacies, both in the control group and in the experimental group, the same 
adherence support intervention was to be implemented, which consisted of the 
following procedure.
A first consultation with the pharmacist took place after the patient had given 
informed consent (T0). Several aspects of the patient’s experience with the 
antihypertensive medication were discussed according to a prespecified protocol. Next, 
the pharmacist explained the function and mode of operation of the Medication Event 
Monitoring System (MEMS; Aardex, Zug, Switzerland)11,13 to the patient and chose one 
antihypertensive drug for which adherence was to be measured. Preference was given 
to a drug of which nonadherence was expected on the basis of the past refill rate and 
the patient’s information, or, if refill rate was expected to be the same for all 
antihypertensive drugs used, in the following order: diuretic; B-blocking agent; calcium 
channel blocker with mainly vascular effect; agent acting on the renin angiotensin
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system; other antihypertensive drug, which is the order in which poor adherence 
generally decreases17,18.
About 2 months after the first consultation (T1), the pharmacist discussed the MEMS 
data with the patient and later handed them over to the patient’s GP. The GP decided 
whether any medication changes were to be made on the basis of the electronically 
measured medication adherence and blood pressure at T1. Five months after the first 
consultation blood pressure was measured for the third time (T2). No patient-directed 
intervention other than a possible medication change occurred between T1 and T2. 
D ir ec t e d  a t  p h a r m a c ie s— e x p e r im e n t a l  g r o u p
The intensive implementation programme directed at pharmacies, which was 
developed to overcome barriers and to use facilitators for implementation of the 
adherence support in this study, was based on previous research19-24 and on the 
extensive experience of two professional communication advisors who were well- 
informed about daily practice in community pharmacies. It consisted of an educational 
manual with information about the project; two interactive educational meetings for 
the pharmacists; and at least two reminder and support telephone calls by a research 
assistant in which the progress of the project and any need of more help were 
discussed. Any additional telephone calls were planned by mutual arrangement.
D ir ec t e d  a t  p h a r m a c ie s— c o n t r o l  g r o u p
Pharmacists in the control group received the written educational manual at the start 
of the study. No further implementation support was given.
D ir ec t e d  a t  t h e  g e n e r a l  p r a c t ic e
In each participating general practice, GPs and/or practice nurses and/or practice 
assistants (depending on the choice of the GP) were instructed on location by the 
researchers in the purpose of the study, inclusion and follow-up of patients, 
cooperation with the pharmacy and blood pressure measurement.
Measurements
Relevant pharmacy characteristics which could influence the pharmacist’s care- 
providing function24,25 were collected to assess the comparability of the randomized 
groups. Descriptive information regarding the implementation process was reported by 
the pharmacists at the end of the project by means of a written questionnaire. Barriers 
and facilitators for the implementation were extracted from this questionnaire and 
were also collected by the research assistants on the basis of the telephone 
conversations they had with the pharmacists in the experimental group. The number of 
patients potentially eligible for adherence support was reported by the participating 
pharmacists by means of a count over 2 weeks of all patients who already used at least 
one antihypertensive drug and who received a prescription for an additional 
antihypertensive drug or an increase in dosage.
82 Implementation of adherence support for patients with hypertension
A trained GP, general practice nurse, general practice assistant, or pharmacist 
measured patients’ blood pressure at inclusion (T0), 2 months after inclusion (T1), and 
5 months after inclusion (T2) by means of the automated Microlife BP 3AC1-1 monitor 
(Microlife AG, Widnau, Switzerland). Patients were in the sitting position and had 5 
minutes of rest before the measurement. The mean SBP and the mean diastolic blood 
pressure (DBP) were recorded after three consecutive measurements with 15 seconds 
in-between. The three measurements were averaged automatically. Medication 
adherence was measured for one antihypertensive drug per patient by means of the 
MEMS. The percentage adherence was calculated as the number of MEMS openings from 
the day after the first consultation with the pharmacist until the day of the second 
consultation with the pharmacist, divided by the number of prescribed doses for that 
period. Patient characteristics, baseline use of antihypertensive medication and 
medication changes during follow-up were reported by the pharmacists on a written 
form. Defined daily doses were calculated using the World Health Organization 
ATC/defined daily dose methodology26. Treatment intensification was defined as an 
increase in the total number of defined daily doses.
Outcomes
The primary outcome was the number of patients included in the electronic monitoring 
programme. Secondary outcomes were the mean change in SBP in the included patients 
and the percentage of patients with adequate SBP control (i.e., <140 mm Hg).
Sample size
In a previous implementation trial among community pharmacies, about one-third of 
the pharmacies in the control group vs. two-thirds of the pharmacies in the 
experimental group implemented a pharmaceutical care project relatively 
successfully24. Assuming that the mean number of patients being included in each 
pharmacy would be 3 in the control group and 6 in the experimental group, 16 clusters 
of pharmacies were required in both groups to detect a significant difference (P = 0.05, 
two-sided), based on a power of 0.8 and a s.d. of 3.
Statistical analysis
Differences in baseline characteristics between the control and the experimental group 
of pharmacists and patients were tested for using unpaired t-tests and X2-tests. The 
impact of the intensive implementation programme on the inclusion of patients into 
the study and on other indicators for the success of implementation was examined in a 
random coefficient regression model, which took into account that pharmacies were 
grouped within pharmacy clusters. The primary analysis was intention-to-treat. P 
values of 0.05 or less (two-sided) were considered significant. Patient outcomes were 
analyzed by means of descriptive analysis. Data were analyzed using the SPSS 16.0
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software package, except the random coefficient regression analysis, which was 
performed using the SAS 9.1.3 software by means of the GLIMMIX procedure.
Results
Baseline characteristics
Figure 1 shows the flow of participants throughout the study. Randomization of the 57 
pharmacies who registered for participation resulted in a control group of 25 
pharmacies in 12 pharmacy clusters and an experimental group of 32 pharmacies in 12 
pharmacy clusters.
Figure 1. Participant flow
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As is shown in Table 1, one cluster was much larger than the other clusters. As a 
consequence, the study groups ended up very uneven.
Table 1. Clustering of participating pharmacies
Number of pharmacies in cluster Frequency Number of pharmacies
1 10 10
2 4 8
3 6 18
4 3 12 
9 1 9
Total: 24 clusters Total: 57 pharmacies
Table 2 presents characteristics of participating pharmacies which could influence the 
pharmacist’s care-providing function24,25 and the other characteristics we considered. 
Baseline characteristics were similar in both groups, except for two characteristics: the 
mean number of years in service of the managing pharmacist was higher in the 
experimental group and more pharmacists in the experimental group had a good or very 
good relationship with the GPs.
Table 2. Pharmacy characteristics at baseline
Experimental Control P-value
(N=30) (N=22)
Number of years in service pharmacist3 15.5 ± 8.3 11.1 ± 5.1 0.032
Frequency of postgraduate training in pharmacotherapy for
pharmacist: regularly or often 22 (73.3) 19 (86.4) 0.256
Attitude regarding care-providing function (continuous scale of 
80)a;b
Pharmacy technicians with specialized care-providing duties
16- 67.6 ± 6.7 64.9 ± 6.1 0.137
26 (86.7) 19 (86.4) 0.975
Relationship with GP: good or very good c 24 (82.8) 12 (54.5) 0.029
Workload as perceived by pharmacist: high or very high c 12 (41.4) 10 (45.5) 0.771
Pharmacy is part of chain or franchise formula d 23 (76.7) 14 (66.7) 0.431
Participation in study because of perception of pressure from
insurance company: partly or completely agree c 2 (6.2) 3 (13.6) 0.423
Data are absolute scores with the percentage between brackets, unless otherwise specified.
a Data are mean scores ± SD
b Attitude was measured using the statements described in the Appendix of Chapter 5 (page 75). 
c N=51 pharmacies: 22 in the control group and 29 in the experimental group 
d N=51 pharmacies: 21 in the control group and 30 in the experimental group
Success of the implementation
Table 3 shows the effects on measures of the implementation process. In many 
pharmacies a range of planned activities had been undertaken. None of the measures 
showed significant differences between the experimental and the control group, but 
the experimental group yielded consistently higher scores than the control group. The 
mean number of patients included in the study, which was the primary outcome 
measure, was 1.6 in the experimental group vs. 1.0 in the control group (P=0.28) within
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a period of between 3 and 9 months. In total, 24 patients were included in the control 
group, vs. 50 patients in the experimental group. The success of implementation was 
not equally divided about the pharmacies: the four most successful pharmacies 
included 29 patients, which was 39% of all patients included. Three of these 
pharmacies were in the experimental group, one pharmacy was in the control group.
Of the patients who were referred to the pharmacy by the GP, two patients did not 
want to participate; one patient was treated for hypertension by a medical specialist 
only; and three patients were not included by the pharmacist because of organizational 
difficulties. Additionally, 12 patients were excluded blindly by the researchers, because 
they did not meet the inclusion criteria: 8 patients had a SBP <150 mm Hg and 4 
patients had a SBP >180 mm Hg.
Table 3. Success of the implementation - process outcomes
Experimental Control Effect size P-value
(N=32 (N=25 (95% CI)
pharmacies in pharmacies in
12 clusters) 12 clusters)
Pharmacies which introduced the project to 27 (84.4) 20 (80.0) 1.25 (0.20;8.03) 0.81
at least 1 GP
Pharmacies with at least 1 cooperating GP 20 (62.5) 10 (40.0) 2.77 (0.48;16.04) 0.25
Pharmacies to which at least 1 patient was 20 (62.5) 9 (36.0) 3.60 (0.62;20.86) 0.15
referred for intake consultation
Pharmacies which included at least 1 patient 18 (56.2) 9 (36.0) 2.82 (0.52;15.14) 0.22
GPs to whom project was introduceda 3.2 ± 4.1 5.3 ± 6.6 -2.1 (-4.9;0.8) 0.65
GPs who referred at least 1 patient to the 1.2 ± 1.7 0.7 ± 1.0 0.5 (-0.6;2.3) 0.25
pharmacya
Patients who were referred to pharmacy for 2.0 ± 2.6 1.4 ± 2.3 0.6 (-1.38;2.3) 0.56
intake consultationa
Patients who were includeda 1.6 ± 2.3 1.0 ± 1.6 0.7 (-0.6;2.0) 0.28
Patients who were included in pharmacies 2.9 ± 2.4 2.7 ± 1.5 0.2 (-1.6;2.0) 0.80
which included at least 1 patienta
CI, confidence interval; GP, general practitioner 
Data are absolute scores (% in brackets), effect size is OR 
a Data are mean scores ± SD, effect size is difference
Patient outcomes
Baseline characteristics of patients and patient outcomes are shown in Table 4. 
Because there were no differences in the main outcomes between patients in the 
experimental group and patients in the control group, the results of all patients are 
discussed together. Each patient used between one and four different antihypertensive 
drugs at inclusion and >90% of the drugs were taken once a day. The mean refill rate of 
all antihypertensives used was 95.7% in the year before inclusion. The mean blood 
pressure at inclusion was 163/90 mm Hg.
Table 4. Patient characteristics and outcomes
TO T1 T2
Experimental Control Experimental Control Experimental Control
(N=50) (N=24) (N= 50) (N=24) (N= 50) (N=24)
Age (years) 63.2 ± 9.2 66.1 ± 10.6
Male a 27 (54.0) 10 (41.7)
Total DDDs of antihypertensives used 2.1 ± 1.3 1.9 ± 1.3
Dosage frequency per day 1.1 ±0.2 1.0 ±0.2
Number of different antihypertensives used 2.0 ±0.8 1.8 ±0.8
Number of patients who used:
Diuretics “ 37 (74.0) 14 (58.3)
Beta blockers “ 20 (40.0) 16 (66.7)
Calcium antagonists “ 7 (14.0) 2 (8.3)
Agents acting on the RAS “ 37 (74.0) 10 (41.7)
Other antihypertensives 0 0
Refill rate
Mean refill rate in % 95.2 ± 9.7 b 97.1 ± 5.4 b
Patients with refill rate > 85% a 41/46 (89.1) 19/20 (95.0)
Adherence with MEMS (in %) 98.9 ± 2 .7 c 98.6 ± 2.7
SBP in mm Hg 163.1 ± 7.4 162.6 ± 8.9 154.2 ± 12.6 d 157.5 ± 16.0 149.5 ± 14.9 f 151.8 ± 13.6 f
DBP in mm Hg 90.9 ± 10.2 89.5 ± 11.2 87.1 ± 9.0 e 85.5 ± 12.5 84.0 ± 10.3 f 83.8 ± 9.8 f
Mean change in SBP compared to TO -9.0 ± 11.6 e -5.1 ± 14.9 - 12.8 ± 15.0f -10.6 ± 15.6 f
Mean change in DBP compared to TO -3.6 ± 7 .4 f -4.0 ± 6.2 -6.2 ± 9.6 f -6.4 ± 6 .4 f
Patients with SBP < 140 mm Hg a 6 (12.2) 4 (16.7) 9 (20.5) 5(21.7)
Patients with SBP < 150 mm Hg (which was inclusion 22 (50.0) 8 (34.8)
criterion)3
Patients with treatment intensification “ 17 (34.0) 7 (29.2)
Mean change in DDDs compared to TO 0.26 ± 0.60 g 0.20 ± 0.43 g
Patients without treatment intensification:
SBP < 140 mm Hg “ 4/33 (12.1) 3/17(17.6) 7/30 (23.3) 2/16 (12.5)
SBP > 140 mm Hg but change in SBP > 10 mm Hg 18/29 (62.1) 13/14 (92.9) 9/23 (39.1) 10/14 (71.4)
compared to TO “
DDD, defined daily dose; RAS, renin angiotensin system; MEMS, Medication Event Monitoring System; SBP, systolic blood pressure; DBP, diastolic blood 
pressure.
Data are mean scores ± standard deviation unless otherwise specified
a Data are absolute scores (% in brackets); b refill data were available for only 46 patients in the experimental group and 20 patients in the control 
group; c MEMS data available for 49 patients only; d SBP at T1 was available for 49 patients only; e DBP was available for 48 patients only; f SBP and 
DBP at T2 were available for only 44 patients in the experimental group and 23 patients in the control group; s change in DDDs was available for only 
49 patients in the experimental group and 23 patients in the control group.
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After 2 months of electronic monitoring without any medication changes (i.e., at T1),
the mean change in blood pressure was -8/-4 mm Hg. Five months after the intake
consultation (i.e., at T2), mean blood pressure had changed by -12/ -6 mm Hg
compared to TO and SBP was <140 mm Hg in 20.9% of the patients. In 13.6% of the
patients control of SBP was achieved without treatment intensification.
Barriers and facilitators
Table 5 shows the barriers and facilitators which experimental pharmacists reported
during the reminder and support telephone calls. Lack of time in both general practice
and pharmacies was the predominant barrier, which obstructed the pharmacists to get
started and to obtain involvement of GPs in the project.
Table 5. Barriers and facilitators for the implementation reported by experimental pharmacists
Barriers related to the: Influenced which step of Frequency of
implementation process reporting
(number of
pharmacies)
Organizational context
Lack of time or staff in general practice Involvement of GPs and 12
patient inclusion
Lack of time or staff in pharmacy Getting started 4
Use of other blood pressure monitor Patient inclusion 1
Slow start in general practice Patient inclusion 1
Allocation of tasks between general practice and pharmacy Consultations 1
Individual professional
Low outcome expectations of GP or pharmacist Involvement of GPs 4
GPs forgot to refer patients to pharmacist Patient inclusion 3
GPs did not want to harm basis for trust with patient Patient inclusion 3
Patient
Patients did not want to participate Patient inclusion 1
Social context
Absence of extra remuneration for GPs in the project Involvement of GPs 2
Role of health insurance company Involvement of GP and 2
pharmacist
Facilitators related to the:
Organizational context
Delegation of GP’s tasks to practice nurse Involvement of GPs 5
Limited time investments required for GPs Involvement of GPs 5
Individual professional
Positive attitude of the GP towards the project Involvement of GPs 9
Positive attitude of the GP towards health care research Involvement of GPs 1
Intensive implementation programme
Reminder and support telephone calls with pharmacists Start and follow up 10
Additional barriers which were reported more than once were low outcome 
expectancies from GPs, either because they did not expect many patients to be eligible 
for adherence support, or because they expected a high degree of adherence when
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patients used the MEMS monitor and did not understand that the degree of adherence 
measured with electronic monitoring was not the primary aim of the study; GPs who 
stated that they forgot to refer patients to the pharmacy; GPs who were afraid they 
would harm the relationship with the patient based on mutual trust; and a negative 
view on the role of the health insurance company which funded the present study in 
the promotion of mail-order pharmacy and general practice transparency.
Facilitators reported more than once by the pharmacists were limited time investment 
for the GP; delegation of tasks to the practice nurse; and a positive attitude of the GP 
toward the project. The pharmacists in the experimental group appreciated the 
reminder and support telephone calls from the research assistants as a facilitator.
Discussion
More pharmacies in the experimental group had included at least one patient compared 
to the control group, but the difference between the groups did not reach statistical 
significance. The number of patients included fell far below our expectations, although 
the relative difference between intervention and control groups was in line with our 
expectations. The part of the implementation process which was primarily affected by 
the barriers perceived by the pharmacists, was the involvement of GPs in the study, 
followed by the inclusion of patients by the GP. Although the intensive implementation 
programme had a moderately better effect on pharmacist performance (i.e., more 
pharmacies with at least one cooperating GP and more pharmacies which included at 
least one patient), it was apparently not sufficient to overcome all barriers, because 
the number of patients included in the MEMS programme remained low in the 
experimental group.
The question why this was the case remains unanswered. One possible explanation 
might be that only a few patients in general practice were eligible for the adherence 
support. This seems unlikely, however, because on average nine patients per 
participating pharmacy had an intensification of antihypertensive treatment in a period 
of 2 weeks. Another possible reason involves limited patient enrolment, which can be a 
problem for any busy practitioner. In our situation, GP practices did not register for 
participation in our study themselves, but they participated via pharmacies, which 
might have made the problem even larger. However, in the study of Wetzels et al.13, 
which targeted GPs directly, the average inclusion rate was comparable with ours. A 
third reason may have been that the GPs did not identify or pass on eligible patients. It 
has been shown that intensification of antihypertensive drug regimens does not always 
occur when an elevated blood pressure is established27. Many physicians seem to be 
insecure whether it is permissible to allow some patients to maintain an elevated blood 
pressure28 or have the misconception that a patient’s blood pressure is usually well 
controlled29. A final reason for the limited inclusion of patients in the MEMS programme
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may have been that patients might have indicated to their GP that they were not 
interested in the MEMS programme. More research is needed to clarify these issues.
The mean change in SBP was -12 mm Hg and in one out of every eight patients the SBP 
was controlled after 5 months, without treatment intensification. Some of this 
improvement may be caused by regression to the mean, as we only included patients 
with high-blood pressure, or by the Hawthorne effect. The results were comparable 
with the findings of previous studies11,13, if we take into account that the patients’ SBP 
in our study had to drop at least 10 mm Hg before SBP was <140 mm Hg, as a 
consequence of our inclusion criteria11,13. It seems plausible that the effect of the MEMS 
is based on the MEMS itself, which can be so powerful that the communication 
technique used in the consultation does not have much additional effect. A special 
value of the MEMS intervention seems to be, that improved blood pressure control was 
reached despite the fact that refill rate was very high at baseline. We can only 
speculate about the mechanism of this action. Possibly, the awareness of patients 
being “observed” by the MEMS forced them to take their medication. For the patients 
who had SBP control without a need for treatment intensification, the positive effect of 
adherence to their antihypertensive therapy was shown, which could have motivated 
them to keep taking the medication faithfully. The GPs gained insight into the 
medication taking behavior of their patients, which provided a base for the decision on 
whether to intensify treatment or not. However, most patients who did not reach 
hypertension control did not receive treatment intensification, despite good 
medication adherence. Clinical inertia still seemed to be a problem in this study. 
Involving a pharmacist in team-based hypertension care has been proven effective in 
reducing blood pressure and achieving blood pressure control in a review of team-based 
care interventions for hypertension30. Especially pharmacists recommending medication 
to the physician was highly associated with significant reductions in mean SBP. In 
general, adding enhanced clinical expertise to patient care teams improves professional 
performance31. Further research should combine the patient-directed MEMS with an 
expanded role of the pharmacist in the hypertension care team (both identification of 
patients with uncontrolled hypertension and recommendations about medication to the 
physician).
Both refill adherence before the adherence support and adherence measured by means 
of the MEMS were very high in this study and adherence rates assessed by electronic 
monitoring are generally high both in Europe and in the United States14. On the 
contrary, refill adherence with antihypertensive drugs varies between about 50 and 85% 
in the United States32,33. High adherence is associated with better blood pressure 
control34, which is probably the reason why MEMS can be used to optimize blood 
pressure. In this light, the effect of MEMS on blood pressure might be even larger in the 
United States. In The Netherlands, all patients are registered to a single GP who has a 
gatekeeper role in coordinating medical care. All residents have an obligatory health
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insurance, which covers physician consultation and most medication. So, cost will not 
hamper physician visits nor drug refills. It is remarkable, however, that almost one-fifth 
of the patients who did not receive treatment intensification reached blood pressure 
control after 2 months of MEMS monitoring. Apparently, they filled their drug 
prescriptions regularly, but it is not known whether they actually took their 
medications every day.
The present study has strengths and weaknesses. Among the strengths were the 
randomized design and low drop-out rate for the pharmacies in addition to the choice 
of a simple method for adherence support. A weakness was that of the 158 pharmacies 
invited for participation, only 57 actually registered for our study. Unfortunately, we 
were not able to determine why pharmacies chose not to participate or whether they 
were comparable to the pharmacies that were enrolled in the study.
It is therefore unclear to which extent voluntary participation may have lead to bias. 
The number of participating pharmacies is this study was smaller than we needed 
according to our sample size calculation. As a consequence, the power to detect a 
significant difference might have been too low. The effect size was also much smaller 
than we expected, so a sample of 16 clusters per group which had been required 
according to our sample size calculation would neither have been large enough to reach 
a statistically significant result. We suggest that the relative differences be considered 
in the interpretation of the results. Some of the observed improvements in blood 
pressure might have been caused by regression to the mean and/or by the Hawthorne 
effect, as we only included patients with high-blood pressure. Note that the study was 
not designed to examine the effectiveness of MEMS on blood pressure.
In conclusion, the MEMS is a simple way of adherence support which can decrease the 
need for treatment intensification once it has been put into action. An intensive 
implementation programme directed at pharmacists was insufficient to overcome all 
problems with the implementation of the MEMS application in daily practice. More 
research is needed, especially to determine how patients with uncontrolled 
hypertension despite the use of antihypertensive medication can be identified in 
general practice.
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The central aim of the research presented in this thesis was to examine the impact of 
intensively supported implementation of specific pharmaceutical care services in 
community pharmacies. Four services were studied: 1) sending a discontinuation letter 
to long-term benzodiazepine users; 2) improving general practitioner prescribing of 
statins for patients with atherothrombotic cardiovascular disease; 3) providing patient 
education at first and second dispensing of statins; and 4) assessing adherence with 
antihypertensive medication of patients with uncontrolled hypertension. We also 
described the usefulness of antiplatelet prescriptions as a tool to identify patients with 
atherothrombotic cardiovascular disease (ACD) in order to improve statin prescribing 
for these patients. This was important, because antiplatelet medication seems a 
feasible marker for ACD in theory, but might be less so in daily practice. In this final 
chapter we will discuss the main findings from our studies and discuss these in relation 
to other research. We will summarize the main overall study limitations and then 
suggest implications of our findings for future research and practice.
Main findings and conclusions
Table 1 summarizes the main results of our evaluation of the four pharmaceutical care 
services, in which we distinguish between a) activities of pharmacists and general 
practitioners (GPs) in the care delivery process; b) the extent to which pharmaceutical 
care was actually provided to patients; and c) patient behaviours and outcomes.
In a nutshell, we found that intensively supported implementation by pharmacists 
and/or pharmacy project assistants resulted in improved performance of activities as 
planned in each of the projects, but in little change in the provision of pharmaceutical 
care, in patient behaviours or in outcomes. In each of the studies, between a quarter 
and half of the pharmacies in the control group performed planned activities to a 
certain extent, although they received little support. In the experimental group of each 
of the studies, this was the case in between one third to two thirds of the pharmacies. 
Despite these activities, however, only a small minority (5% to 25%) of the patients 
eligible for specific pharmaceutical interventions actually received these, with little 
difference between the study groups.
Table 1. Overview of study findings of experimental group pharmacies versus control group pharmacies
Study Activities of pharmacists and 
GPs
Pharmaceutical care received by patients Patient behaviours and outcomes
Discontinuation letters for 81% vs. 51% of pharmacists 
long-term benzodiazepine handed over list to GP 
users (chapter 2) 72% vs. 47% of pharmacists 
retrieved at least 1 list 
38% vs. 30% of GPs returned list 
43% vs. 26% of pharmacies sent 
letters within 4 months 
70% vs. 40% of pharmacies sent 
letters within 8 months
14% vs. 9.5% of patients received letter # 9.9% vs. 10.2% of patients stopped after 
6 months
15.9% vs. 16.7% of patients reduced use 
by at least 50% after 6 months
Statin prescribing for 
patients with 
atherothrombolic 
cardiovascular disease 
(chapter 4)
94.1% vs. 87.1% of pharmacists 
handed over list to GP 
47.1% vs. 54.8% of pharmacists 
retrieved at least 1 list 
21.2% vs. 15.9% of GPs returned 
list
19.7% vs. 10.8% of patients 
reviewed for indication by GP(D
5.8% vs. 5.3% of patients received a statin 
after 6 months #
9.9% vs. 9.3% of patients received a statin 
after 12 months 
14.4% vs. 15.6% of patients with an indication 
received a statin after 6 months 
19.2% vs. 26.6% of patients with an indication 
received a statin after 12 months
n.a.
Education to patients who 
received a statin for the 
first time (chapter 5)
50.0% vs. 45.2% of pharmacies 
offered EAFD 
35.3% vs. 38.7% of pharmacies 
offered EASD
15.4% vs. 19.4% of patients with a first statin 
prescription received EAFD #
12.5% vs. 10.2% of patients with a second 
statin prescription received EASD
93.9% of patients who received EAFD had 
a second statin prescription filled vs. 
83.2% of patients who did not receive 
EAFD *
80.7% of patients who received EAFD as 
recommended still used a statin after 6 
months vs. 77.0% of patients who did 
not receive EAFD as recommended* 
91.2% of patients who received EASD still 
used a statin after 6 months vs. 83.2% 
of patients who did not receive EASD *
Electronic monitoring of 84.4% vs. 80.0% of pharmacists 
treatment adherence in introduced project to GP 
uncontrolled hypertension 62.5% vs. 40% of pharmacies had 
patients (chapter 6) at least 1 cooperating GP
56.2% vs. 36.0% of pharmacies 
__________________________included at least 1 patient
1.6 vs. 1.0 patients received electronic 
monitoring #
Mean SBP reduction of 12.8 vs. 10.6 mm 
Hg
20.5% vs. 21.7% of patients reached SBP 
<140 mm Hg
# Primary outcome; (D This was the only outcome which was significantly different between intervention group and control group.
* Comparison between patients who did vs. patients who did not receive pharmaceutical care, not between experimental vs. control group.
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Our process evaluations did not provide clear insight into factors consistently related to 
the success of implementation. Nevertheless, we suggest that an important factor is 
the role of general practitioners in identifying patients eligible for a discontinuation 
letter, a statin or the MEMS intervention and in prescribing statins.
In conclusion, a written manual in which all steps of the implementation process are 
described in detail will be sufficient for a quarter to half of pharmacies to get started 
with a simple or more complex pharmaceutical care service. Additional pharmacies (up 
to 30%) will benefit from an intensive implementation strategy comparable to ours. A 
third to half of the pharmacies will need a different approach in order to start 
providing specific pharmaceutical care services. Equally important, or even more 
important: our intensive implementation strategies have hardly influenced clinically 
relevant outcomes, despite the fact that we focused on interventions that had shown 
to be effective.
Interpretation in the light of previous research
The effectiveness of many implementation interventions has been evaluated in a large 
number of Cochrane reviews. Interventions which have been shown consistently to be 
able to improve professional practice are audit and feedback1, educational meetings2, 
educational outreach visits3, and point of care computer reminders4. The median 
improvement of professional practice (e.g. % compliance with guidelines or % of 
patients treated according to guidelines) with these interventions varies between 3% 
and 6%, and the upper quartile varies between 6% and 28%. In this view, the effect of 
our intensive implementation strategies on the actual delivery of pharmaceutical care 
in our studies was small. On the contrary, the increase in pharmacy performance of 30% 
in the benzodiazepine study and of 20% in the MEMS study can be considered large 
effects. However, the large effect of the interventions on pharmacy performance was 
not translated into improved pharmaceutical care in these studies. In addition, our 
intervention did not influence pharmacy performance in the statin study. How should 
we interpret these findings?
It remained unclear in which respect the setting of the statin study differed from the 
other studies and which barriers should have been addressed better to improve statin 
prescribing and education at first and second dispensing. A quarter of the pharmacists 
in the experimental group participated because they felt forced by the health 
insurance company to do so. Nevertheless, even the pharmacists who had disappointing 
results in the benzodiazepine study did not experience a cut back in remuneration. 
Possibly, this may have reduced the motivation of part of the pharmacists. It is unlikely 
that complexity of the intervention played a role in the lack of improvement of 
pharmacy performance in the statin study, because the implementation came to a 
standstill before the pharmacists’ task became more complex than for example in the 
benzodiazepine study.
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The large increase in pharmacy performance in the benzodiazepine study and in the 
MEMS study might have been related to the relative simplicity of the activities and the 
relatively limited time investment. Prescribing statins and providing education to a 
large group of patients require more investments from GPs and pharmacists, both in 
time and in organization of the care process. After the statin study, we performed an 
unreported qualitative study amongst 20 GPs who were contacted by pharmacists to 
cooperate5. A substantial number of these GPs would have appreciated practical 
assistance with a project. Future research should investigate whether organizational 
and practical support of GPs in addition to the support of the pharmacists improves 
statin prescribing.
Thus, the major question was how to interpret the lack of translation of extra 
pharmacy performance to actual pharmaceutical care provision. An explanation for this 
would be that the pharmacists were largely dependent upon the GPs in delivery of 
pharmaceutical care. According to Chen and De Almeida Neto6, mutual trust is the basis 
for cooperation and the quality of interaction is dependent on trust. Other studies 
indicate that besides mutual trust, a clear-shared expectation of collaboration, role 
specification, and routine face-to-face interactions are important for professional 
collaboration between pharmacists and physicians6-8. In addition, shared - or at least 
not conflicting - clinical priorities and financial interests may be needed for effective 
collaboration. In the qualitative study mentioned above, a substantial number of the 
GPs reported that they were disappointed that the project was not designed and 
started in consultation with them. Next, most of the GPs questioned believed that the 
pharmacist did not only participate in the study in order to benefit the patients, but 
also because of a financial benefit for themselves. In addition, a substantial number of 
GPs did not want the pharmacist to interfere with the GPs’ task, or did not want to 
account for their actions to the pharmacist. Apparently, the basis of trust is not self- 
evident. With respect to a clear-shared expectation: GPs mainly appreciate the 
provision of prescribing data by the pharmacist5;9 whereas pharmacists believe that 
they can play an important role in the pharmaceutical management itself. So, the 
development of a basis of trust between pharmacists and GPs and a clear-shared 
expectation of collaboration need extra attention in current practice. By now, there is 
increasing evidence that participation and interventions of pharmacists can positively 
influence the process of clinical practice, clinical outcomes and physicians’ and nurses’ 
drug therapy knowledge, especially if the pharmacist is a member in a multidisciplinary 
team10-14. So, a larger role for the pharmacist in a multidisciplinary team seems to offer 
an important opportunity to improve (pharmaceutical) care for many patients.
A substantial number of the GPs in the above-mentioned qualitative study5 believed 
that a financial incentive would have enhanced the implementation of 
recommendations on pharmacotherapy. However, pay-for-performance has not 
consistently been shown to be an effective method to improve quality of care15. In
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addition, some authors assert that tension exists between the culture of 
professionalism with the fiduciary relationship between patient and physician or 
pharmacist as a central theme, and pay-for-performance16;17. So, whether a different 
remuneration system, e.g. pay-for-performance, can improve the provision of 
pharmaceutical care by GPs and pharmacists remains a subject for further research. 
Another way forward might be that one should focus not only on the type of 
implementation intervention provided, but also on the quality of that intervention and 
the context in which it is provided. With regard to educational interventions, 
characteristics of teachers that enhance or hinder learning; student characteristics that 
increase or inhibit learning; teaching strategies that augment learning; and the use of 
newer technologies to facilitate classroom or distance education may all have potential 
impact18.
It is important to mention that unsuccessful implementation of one of our projects in a 
pharmacy does not necessarily indicate that the full quality of care provided in that 
pharmacy is unsatisfactory as well. A scenario can be thought of, that a project did not 
succeed in a pharmacy because every day high-quality care consumed all resources 
available. However, it seems unfeasible to provide high-level pharmaceutical care to 
all patients by all pharmacists, also the ones with a low intrinsic motivation, in the 
current setting and with the implementation strategies studied.
Study limitations
The intensive implementation strategies we used were largely similar in the different 
trials. We tailored the intervention in the first trial on the basis of hypothesized 
barriers and facilitators for change, based on the available literature, on expectations 
of participating pharmacists and on the judgement of professional communication 
advisors who had much experience in the field of community pharmacy and primary 
care. The interventions in the later trials were based on these sources as well, 
combined with our experiences in the first trial. As outcomes of any implementation 
intervention are heterogeneous, we chose not to adjust the strategy for the following 
trials on the basis of these results. In addition, only intermediate results were available 
of the first trial when we planned subsequent trials.
We did not specifically assess to which extent the pharmacists who participated in our 
studies were representative for Dutch pharmacists as a whole. Two comments are in 
order here. In the first place, characteristics which are easily measurable, such as 
number of patients, rural or urban area, part of a pharmacy chain or franchise formula, 
and so on, did not prove to be determinants for the care-providing function in our 
studies. Secondly, pharmacists participated voluntarily, on the understanding that the 
major health insurance company in the South of The Netherlands exempted 
participants in our trials from writing an annual plan and report of patient care 
activities. A substantial number of pharmacists (between 8% and 17% in the four
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studies) reported that they participated because they felt pressure from the insurance 
company to do so. Also, participants were judged on their efforts and not on the final 
result. It is therefore conceivable that the participants in our studies comprised not 
only of early adopters or the early majority from Rogers’ Diffusion of Innovations19, but 
also of pharmacists in the late majority or laggards categories.
Because all our studies were performed in the South of The Netherlands, in which ‘CZ 
Actief in Gezondheid’ is one of the main health insurance companies, we could not 
determine the influence of this specific insurer or the specific geographical regions in 
which it mainly operates. Furthermore, our findings may not be generalizable to other 
countries, where pharmacists may be more involved in patient care teams than in The 
Netherlands.
Implications for research
As we wrote in the main findings, other implementation strategies than we used are 
needed for a third to half of the pharmacies in order to start providing specific 
pharmaceutical care services. Different strategies should also be developed to 
influence the participation of GPs in pharmaceutical care. One could think of the 
following approaches specifically for this setting:
• According to the Cochrane review by Zwarenstein et al.20 multidisciplinary meetings 
with an external facilitator, who used strategies to encourage collaborative working, 
have been able to increase audit activity and improve care in secondary care 
compared to multidisciplinary meetings without an external facilitator. Whether this 
approach is effective in primary care as well, is a subject for further research.
• Whether a different remuneration system, e.g. pay-for-performance, can improve 
the provision of pharmaceutical care by GPs and pharmacists also remains a subject 
for further research.
• Since the collaboration with GPs in the three trials had so much impact on the 
implementation process, future research in which professional collaboration 
between pharmacists and GPs is targeted should involve GPs directly in the choice 
and operationalization of topics for improvement, in the development of the study 
and in the process evaluation as well.
• We included organizational support in our studies in the form of planning of the 
projects and in the second trial the involvement of a project assistant. In future 
studies, new roles could be introduced for dedicated pharmacy personnel with a 
bachelor degree, e.g. pharmaceutical managers who are trained in among other 
things management, legislation and organization in the pharmaceutical field and/or 
pharmaceutical consultants who are trained in among other things pharmacotherapy, 
pharmaceutical care and quality management.
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• Except for the pharmacists’ attitude towards the care-providing function, we did not 
measure any psychosocial characteristics, like Zardain et al. did, for example21. They 
found that A.S.E. (Attitude, Social influence and self-Efficacy) determinant scores 
with respect to providing pharmaceutical care were positively related to higher 
stages of change from the transtheoretical model of behaviour change by Prochaska 
and Velicer22. These psychosocial characteristics could be incorporated in future 
research investigating the effect of new implementation interventions.
• Because pharmaceutical care should be patient centred and should improve patients’ 
conditions, patient experiences should be evaluated in future research as well.
From the broader perspective or implementation research in general the following
topics need further attention:
• As suggested by Bosch et al.23, barriers should be sought actively from the 
perspectives of different stakeholders in the care process with regard to higher-level 
team functioning, organization and structure of the care process. Subsequently, 
interventions should be designed on the basis of theory-based analysis of these 
barriers. Further research is needed to investigate whether theory-based matching of 
the improvement interventions to the identified barriers will have better results than 
the tailored interventions reviewed by Baker et al.24.
• As a consequence, it may be that implementation of pharmaceutical care is only 
achievable on a short-term basis in settings that have specific characteristics, 
regardless of choice and content of the specific implementation program. For 
instance, the clinical priorities and financial interests of pharmacists and GPs need 
to be matched. Primary care groups for chronic illness care (‘zorggroepen’) may 
offer new chances for pharmaceutical patient care.
Implications for practice
• Organizations which want to support pharmacies with implementing a (simple) 
pharmaceutical care service can start by making available a written manual in which 
all steps of the implementation process are described in detail. This will be 
sufficient for a substantial number of pharmacies to get started. For pharmacies 
which experience difficulties with getting started, an additional interactive 
educational meeting in which individually perceived barriers are targeted, combined 
with supportive follow-up telephone calls can be beneficial.
• In order to improve cooperation of pharmacists and GPs, the development of a basis 
of trust, a clear-shared expectation of collaboration and routine face-to-face 
interactions need extra attention. The incorporation of a pharmacist (without 
commercial interest) in a multidisciplinary primary care team may well be an 
important opportunity to improve (pharmaceutical) care for many patients.
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• Cooperation or integration of individual institutes for the primary education of 
pharmacists and physicians could provide a way to establish the previously 
mentioned basis for trust and a clear-shared expectation of collaboration. For 
pharmacists and physicians who are already settled, joint education with regard to 
e.g. continuity of care or to draw up and execute pharmacotherapeutic treatment 
plans can also serve to improve their interprofessional collaboration. Additionally, 
special attention is needed for attitude building and communication skills of 
pharmacists.
• Division of pharmacists with a primary focus on the operational management of the 
pharmacy on one side and pharmacists specializing in providing patient-directed and 
integrated pharmaceutical care seems warranted to make quick progress. In that 
scenario, motivated pharmacists can choose to provide pharmaceutical care and 
prove their value to GPs, thus building trust.
• Since it appears difficult to implement even simple pharmaceutical care services on 
a large scale, a careful selection should be made of the guideline or innovation that 
is to be implemented in clinical practice. The choice should be based on scientific 
evidence on the effectiveness of innovations, on the patients’ needs and on cost 
effectiveness. The latter is especially important in the light of the sharp rise in the 
ageing population. The so-called “Zorgstandaarden”, i.e. multidisciplinary guidelines 
in which optimal multidisciplinary care for patients with a chronic disease and its 
organization are described, are a good start.
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After its introduction in the last quarter of the 20th century, pharmaceutical care has 
been incorporated more and more in daily pharmacy practice. Nevertheless, drug 
related morbidity is still a significant healthcare problem. Evidence indicates that 
pharmacists can play an important role in detecting, resolving and preventing drug 
related morbidity. For this thesis, we chose to study the implementation of four 
specific pharmaceutical services into community pharmacies: 1) sending 
discontinuation letters to long-term benzodiazepine users; 2) improving statin 
prescribing for patients with established cardiovascular disease; 3) providing patient 
education at first and second dispensing of statins to these patients; and 4) the use of 
an electronic monitoring system to assess medication adherence by patients with 
hypertension despite the use of antihypertensive medication. For each of these topics 
the impact of an intensive implementation strategy was compared with a widely used 
simple implementation strategy, i.e. sending a written manual to pharmacists. We also 
investigated the usefulness of antiplatelet prescriptions as a tool to identify patients 
with established cardiovascular disease for the second trial.
In Chapter 2 the implementation of sending discontinuation letters to long-term 
benzodiazepine users in a cluster-randomized trial is reported. Pharmacies were 
randomized into a group which received intensive implementation support (n= 47) or 
into a control group which only received a written manual (n=43). All pharmacists in 
both groups were meant to carry out the same activities: select potentially eligible 
patients from their computer system; hand over a list with these patients to the 
general practitioners (GPs) involved; instruct the GPs to mark patients actually eligible 
for a discontinuation letter on this list and to return the list to the pharmacist; and 
send discontinuation letters to eligible patients. Although substantially more 
pharmacists in the intensive implementation group sent discontinuation letters at the 
end of follow-up (70% versus 40% in the control group, P=0.069), the percentage of 
potentially eligible patients who received a discontinuation letter within 4 months after 
the start of the study did not differ significantly between both groups: 14% in the 
intensive implementation group versus 10% in the control group (P=0.690). We did not 
confirm the effect of the discontinuation letter on patients’ benzodiazepine use as it 
has been shown in previous efficacy studies, although it is important to notice that this 
study was not designed to investigate that effect. Our intensive implementation 
programme may have been particularly helpful for those pharmacies which had 
difficulties getting started with the intervention. Cooperation with GPs, or specifically 
retrieving patient lists from GPs appeared to be the main barrier in the implementation 
process. Thus, it seems crucial to involve GPs more effectively in implementing the 
discontinuation letter.
Summary
Since a new Dutch guideline on cardiovascular risk management appeared in 2006, with 
the recommendation to prescribe a statin to all patients with atherothrombotic 
cardiovascular disease (ACD), the number of patients eligible for treatment with statins 
increased. An efficient method to identify these patients in primary care was therefore 
required. Chapter 3 describes the usefulness of antiplatelet prescriptions as a tool to 
identify patients with ACD. We analyzed the computerized medical records from 45 
general practices and included 45739 patients who had any record of cardiovascular 
disease, cardiovascular symptoms or cardiovascular medication. Of the 7280 patients 
with a recorded indisputable indication for antiplatelet therapy, 4715 (64.8%) could be 
identified by means of antiplatelet prescriptions. Of the 8718 patients with antiplatelet 
therapy, 5697 (65.3%) had a recorded indisputable or possible indication for 
antiplatelet therapy. Female patients, patients younger than 60 years old, and patients 
having a recorded diagnosis of angina pectoris or diabetes had a higher risk to be 
missed by antiplatelet prescribing records. In conclusion, it would be optimal to use 
both morbidity records and prescription records to identify patients with ACD. Patients 
with antiplatelet prescriptions but without recorded ACD deserve extra attention, 
because they are either treated without a proper indication or need a correction of 
their morbidity records.
The cluster randomized trial we performed to improve statin prescribing for patients 
with established cardiovascular disease is described in Chapter 4. Pharmacies were 
randomized into a group which received intensive implementation support (n= 37) or 
into a control group which only received a written manual (n=34). All pharmacists in 
both groups were meant to carry out the following activities: make a list from their 
computer system with patients who used antiplatelet therapy but not a statin and who 
were thus potentially eligible for statin therapy; hand over these lists to the GPs 
involved; instruct the GPs to mark patients actually eligible for statin therapy on the 
list and to return the list to the pharmacist. Next, the GPs were asked to prescribe a 
statin to the eligible patients. Although pharmacist performance hardly improved, 
twice as many patients were reviewed by GPs for a statin indication in the intensive 
implementation group versus the control group (19.7% versus 10.8%, P=0.023). In spite 
of this, an equally low number of patients in the intensive implementation group and 
the control group received a statin after 12 months (9.9% versus 9.3%, P=0.119). Of the 
patients with a definite indication for a statin according to the GP, 19.2% in the 
intensive implementation group and 26.6% in the control group received a statin after 
12 months follow-up (P=0.404). It seems that the intensive implementation programme 
tackled the main barrier perceived by the pharmacists, i.e. engaging GPs in the 
project, reasonably well, but that it did not overcome GPs’ barriers to actually 
prescribe statins.
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New statin users should receive comprehensive information to support them to use the 
medication safely and effectively. Because patient education is not daily routine in all 
pharmacies yet, we studied the implementation of education at first dispensing (EAFD) 
and education at second dispensing (EASD) of statins. This sequel of the cluster 
randomized trial described in chapter 4 is reported on in Chapter 5. All pharmacies 
were instructed to provide EAFD and EASD to each new statin user. The 34 control 
pharmacies in the trial were guided only by the written manual, which included among 
other things protocols for EAFD and EASD. In the 37 other pharmacies both pharmacists 
and project assistants received intensive implementation support. In the intensive 
implementation group 17 pharmacies (50%) provided EAFD and 12 pharmacies (35.3%) 
provided EASD. In the control group comparable results were reported: 14 pharmacies 
(45.2%, P=0.715) provided EAFD and 12 pharmacies (38.7%, P=0.899) provided EASD. In 
the group which had received intensive implementation support, the patient label was 
read out loud more frequently and more patients received information on the 
indication for the statin than in the control group. Although the study was not designed 
to investigate the effect of EAFD and EASD on statin adherence and persistence, a 
possible positive effect was observed in the short term. In conclusion, the intensive 
implementation programme had not been able to increase the provision of patient 
education. Important barriers appeared to be a rather passive attitude of pharmacists, 
and a low number of new statin users.
The last topic for which we performed a cluster randomized trial was the 
implementation of an electronic monitoring system to assess medication adherence by 
patients with uncontrolled hypertension despite the use of antihypertensive 
medication, which is described in Chapter 6. Again, the participating pharmacies 
(n=57) were randomized into a group which received intensive implementation support 
(n= 32) or into a control group which only received a written manual (n=25). The 
activities all pharmacies were expected to carry out were: introducing the project to at 
least one GP; having an intake consultation with patients who were referred by the GP 
and providing the patients with an electronic monitoring system; discussing medication 
adherence with the patient two months later and handing over the results of electronic 
monitoring to the GP. The intensive implementation group scored consistently higher 
on pharmacy performance than the control group, although none of the outcomes 
showed significant differences between the two groups. The mean number of patients 
included for electronic monitoring was 1.6 in the intensive implementation group 
versus 1.0 in the control group (P=0.28). The four most successful pharmacies included 
39% of all patients included into the study. The effect of electronic monitoring in this 
implementation study was comparable to the findings of previous efficacy studies. The 
total number of patients included fell far below our expectations. According to the 
pharmacists in the intensive implementation group, a lack of time both in general
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practice and in the pharmacy was the main barrier. Other barriers were low outcome 
expectancies from GPs; GPs forgetting to refer patients to the pharmacy; GPs being 
afraid to harm the relationship based on mutual trust with the patient; and a negative 
view of pharmacists and GPs on the role of the health insurer which funded this study 
in the promotion of mail-order pharmacy and general practice transparency.
The main findings of the studies in this thesis are discussed in Chapter 7. In a nutshell, 
a written manual in which all steps of the implementation process are described in 
detail will be sufficient for a quarter to half of community pharmacies to get started 
with a simple or a more complex pharmaceutical care service. Additional pharmacies 
(up to 30%) will benefit by an intensive implementation strategy comparable to ours. A 
third to half of the pharmacies will need a different approach in order to start 
providing specific pharmaceutical care services. Equally important, or even more 
important: our intensive implementation strategies have been insufficiently able to 
influence the processes in which GPs are involved and which are vital to ensure that 
more patients receive pharmaceutical care. Compared to other implementation 
interventions, our intensive implementation strategies resulted in relatively large 
increases in pharmacy performance. However, these improvements in pharmacy 
performance were not translated into improved pharmaceutical care to patients. In 
addition, the pharmacy performance in the statin studies were hardly influenced by the 
intensive implementation support. Several interpretations for these findings are given 
in this chapter. Finally, the implications for research and practice are mentioned. 
Future research should examine the effect of: multidisciplinary meetings (including a 
pharmacist) in primary care with an external facilitator; different remuneration 
systems; involving GPs directly in the development and evaluation of implementation 
projects; new roles of dedicated pharmacy personnel; and theory-based matching of 
improvement interventions to actively sought barriers. In addition, psychosocial 
characteristics of healthcare providers and patient experiences should be measured in 
future research. Recommendations for practice include: advice on how to support 
pharmacies for organizations which want to implement pharmaceutical care services; 
the incorporation of a pharmacist in a multidisciplinary primary care team; joint 
education for pharmacists and physicians; a division of pharmacists with a primary 
focus on the operational management and logistics of the pharmacy on one side and 
pharmacists specializing in providing patient-directed and integrated pharmaceutical 
care on the other side; and careful selection of the guideline or innovation that is to be 
implemented into clinical practice. We expect that implementation of effective 
pharmaceutical services is substantially better if these preconditions have been met.
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Het begrip farmaceutische patiëntenzorg (FPZ) werd in de laatste kwart eeuw van de 
20ste eeuw geïntroduceerd en is sindsdien steeds meer een onderdeel geworden van de 
dagelijkse apotheekpraktijk. Geneesmiddelgerelateerde morbiditeit is echter nog 
steeds een belangrijk probleem in de gezondheidszorg. Eerder onderzoek heeft 
aangetoond dat apothekers een belangrijke rol kunnen spelen bij het opsporen, 
oplossen een voorkomen van geneesmiddelgerelateerde morbiditeit. In dit proefschrift 
hebben we ervoor gekozen om de implementatie van vier specifieke activiteiten van 
openbare apotheken te bestuderen: 1) het versturen van stopbrieven aan mensen die 
langdurig benzodiazepines gebruiken; 2) het verbeteren van het voorschrijven van 
statines aan patiënten met manifeste hart- en vaatziekten; 3) het geven van eerste en 
tweede uitgiftebegeleiding aan deze patiënten; en 4) het gebruik van een elektronisch 
volgsysteem om de therapietrouw vast te stellen bij patiënten met ongecontroleerde 
hypertensie ondanks het gebruik van medicatie. Voor ieder van deze onderwerpen is 
het effect van een intensieve implementatiestrategie vergeleken met een eenvoudige 
implementatiestrategie, namelijk het versturen van een projectmap aan apothekers. 
Daarnaast hebben we onderzocht hoe goed patiënten met manifeste hart- en 
vaatziekten in de tweede trial te identificeren zijn door middel van voorschriften voor 
plaatjesremmers.
In Hoofdstuk 2 wordt de implementatie van het versturen van stopbrieven aan mensen 
die langdurig benzodiazepines gebruiken in een cluster-gerandomiseerde trial 
behandeld. Apotheken werden gerandomiseerd in een groep die intensieve 
implementatie ondersteuning kreeg (n=47) of in een groep die alleen een projectmap 
ontving (n=43). Alle apothekers in beide groepen werden geacht dezelfde activiteiten 
uit te voeren: uit het apotheek informatiesysteem selecteren van patiënten die 
mogelijk in aanmerking komen voor de stopbrief; de lijsten met deze patiënten 
overhandigen aan de betrokken huisartsen; huisartsen vragen om de patiënten aan wie 
daadwerkelijk een brief verstuurd kon worden te markeren op de lijst en daarna de 
lijst terug te geven aan de apotheker; en versturen van stopbrieven aan deze 
patiënten. Hoewel aanmerkelijk meer apothekers in de intensief ondersteunde groep 
stopbrieven hadden verstuurd aan het einde van de onderzoeksperiode (70% versus 40% 
in de controle groep, P=0,069), was er geen verschil tussen beide groepen in het 
percentage van de geselecteerde patiënten dat binnen 4 maanden na de start van het 
onderzoek een stopbrief kreeg: 14% in de intensief ondersteunde groep versus 10% in de 
controle groep (P=0,690). We hebben het effect van de stopbrief op het 
benzodiazepinegebruik van patiënten zoals dat is gevonden in eerdere studies niet 
kunnen bevestigen. Daarbij is het belangrijk om te vermelden dat ons onderzoek niet 
was opgezet om dat te doen. Ons intensieve implementatieprogramma was 
waarschijnlijk vooral nuttig voor apotheken die moeite hadden met de start of de 
uitvoering van het project. De samenwerking met huisartsen, met name het
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terugkrijgen van de patiëntlijsten, bleek het belangrijkste knelpunt in het 
implementatieproces. Het lijkt dus essentieel om huisartsen effectiever te betrekken 
bij het sturen van benzodiazepine stopbrieven.
In de richtlijn Cardiovasculair risicomanagement, voor het eerst gepubliceerd in 2006, 
wordt aanbevolen om een statine voor te schrijven aan alle patiënten met hart- en 
vaatziekten ten gevolge van atherothrombotische processen (HVZ). Het aantal 
patiënten dat in aanmerking komt voor behandeling nam ineens toe door de publicatie 
van deze richtlijn. Daarom was er een efficiënte methode nodig voor de identificatie 
van deze patiënten in de eerste lijn. Hoofdstuk 3 beschrijft de bruikbaarheid van 
voorschriften voor plaatjesremmers om patiënten met HVZ te identificeren. We hebben 
de medisch dossiers uit de computers van 45 huisartspraktijken geanalyseerd met 
daarin 45739 patiënten bij wie tenminste één registratie van hart- en vaatziekte, 
cardiovasculaire symptomen of cardiovasculaire medicatie aanwezig was. Van de 7280 
patiënten met een duidelijke indicatie voor plaatjesremmers kregen er 4715 (64,8%) 
daadwerkelijk minimaal één voorschrift voor een plaatjesremmer. Van de 8718 
patiënten die plaatjesremmers kregen, was er bij 5697 (65,3%) een duidelijke of 
mogelijke indicatie voor een plaatjesremmer geregistreerd. Vrouwen, patiënten jonger 
dan 60 en patiënten met een diagnose van angina pectoris of diabetes kregen minder 
vaak een plaatjesremmer voorgeschreven. Hieruit leiden we af dat voor het opsporen 
van patiënten met HVZ zowel morbiditeitsgegevens als voorschrijfgegevens nodig zijn. 
Patiënten die wel een plaatjesremmer krijgen maar van wie geen HVZ is geregistreerd 
verdienen extra aandacht: ofwel worden zij behandeld zonder een juiste indicatie, of 
de registratie van morbiditeit in hun dossier zou moeten worden aangepast.
De cluster-gerandomiseerde trial die we hebben uitgevoerd om het voorschrijven van 
statines voor patiënten met HVZ te verbeteren wordt beschreven in Hoofdstuk 4. 
Apotheken zijn gerandomiseerd in een groep die intensieve implementatie- 
ondersteuning kreeg (n=37) of in een controlegroep die alleen een projectmap kreeg 
(n=34). Alle apothekers in beide groepen werden geacht om de volgende activiteiten 
uit te voeren: een lijst genereren uit het eigen computersysteem van patiënten die wel 
plaatjesremmers kregen maar geen statine (en die dus mogelijk een indicatie hadden 
voor een statine); deze lijsten overhandigen aan de betreffende huisartsen; de 
huisartsen vragen om patiënten met een daadwerkelijke indicatie voor een statine te 
markeren op de lijst, de lijst vervolgens terug te geven aan de apotheker en tenslotte 
een statine voor te schrijven aan de patiënten met een indicatie. Hoewel de gemeten 
activiteiten van apothekers nauwelijks verschilden tussen beide groepen, werd bij twee 
keer zo veel patiënten uit de intensief ondersteunde groep door een huisarts gekeken 
of er een statine indicatie was ten opzichte van de controlegroep (19,7% versus 10,8%, 
P=0,023). Desondanks kreeg in beide groepen een vergelijkbaar laag aantal patiënten
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een statine 12 maanden na start van het onderzoek (9,9% versus 9,3%, P=0,119). Van de 
patiënten die volgens de huisarts een statine indicatie hadden, kreeg 19,2% in de 
intensief begeleide groep een statine. In de controlegroep was dit 26,6% (P=0,404). Het 
lijkt erop dat het belangrijkste knelpunt dat door apothekers werd verwacht, namelijk 
het betrekken van huisartsen bij het project, redelijk goed werd aangepakt door het 
intensieve implementatieprogramma. Dit programma heeft er echter niet voor kunnen 
zorgen dat huisartsen daadwerkelijk meer statines gingen voorschrijven.
Nieuwe gebruikers van statines zouden goede informatie moeten krijgen om hen te 
ondersteunen bij het veilige en effectieve gebruik ervan. Omdat het op 
gestructureerde wijze geven van informatie nog niet in alle apotheken dagelijkse 
routine is, hebben we de implementatie van eerste en tweede uitgiftebegeleiding (EUB 
en TUB) voor statines onderzocht. In Hoofdstuk 5 wordt verslag gedaan van dit vervolg 
van de cluster-gerandomiseerde trial uit hoofdstuk 4. Alle apotheken werden 
geïnstrueerd om EUB en TUB te geven aan de nieuwe statinegebruikers uit de trial. De 
34 controle apotheken hadden alleen de instructies uit de projectmap met daarin o.a. 
protocollen voor EUB en TUB tot hun beschikking. De apothekers en projectassistentes 
uit de 37 andere apotheken kregen intensieve implementatieondersteuning. In de 
intensief ondersteunde groep werd in 17 apotheken (50%) EUB gegeven en in 12 
apotheken (35,5%) werd TUB gegeven. Vergelijkbare resultaten werden gevonden in de 
controlegroep: in 14 apotheken (45,2%, P=0,715) werd EUB gegeven en in 12 apotheken 
(38.7%, P=0.899) werd TUB gegeven. In de intensief ondersteunde groep werd vaker het 
etiket met de patiënt doorgenomen en meer patiënten kregen informatie over de reden 
van voorschrijven dan in de controlegroep. Hoewel de studie niet was opgezet om het 
effect van EUB en TUB op therapietrouw en blijvend gebruik van statines te 
onderzoeken, werd een mogelijk positief effect daarop op korte termijn gevonden. 
Concluderend kan worden gesteld dat het intensieve implementatieprogramma het 
geven van EUB en TUB niet heeft bevorderd. Een vrij passieve houding van apothekers 
en het kleine aantal nieuwe statinegebruikers leken hierbij belangrijke knelpunten te 
zijn.
Hoofdstuk 6 gaat over het laatste onderwerp waarvoor we een cluster- 
gerandomiseerde trial hebben uitgevoerd: het implementeren van een elektronisch 
volgsysteem om de therapietrouw vast te stellen van patiënten met ongecontroleerde 
hypertensie ondanks het gebruik van antihypertensiva. Ook hiervoor werden de 
deelnemende apotheken (n=57) gerandomiseerd in een groep die intensieve 
implementatieondersteuning kreeg (n=32) of een controlegroep die het moest doen met 
een projectmap (n=25). De activiteiten die door alle apotheken moesten worden 
uitgevoerd waren: introduceren van het project bij minimaal één huisarts; een 
intakegesprek voeren met patiënten die door de huisarts werden verwezen en daarbij
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de antihypertensieve medicatie meegeven in een potje met het elektronische 
volgsysteem; na twee maanden de met het potje gemeten therapietrouw bespreken 
met de patiënt en het resultaat verstrekken aan de huisarts. Hoewel de intensief 
ondersteunde groep consequent beter scoorde op het uitvoeren van de activiteiten dan 
de controlegroep, was er op geen enkele uitkomst een significant verschil tussen de 
groepen. Het gemiddelde aantal patiënten dat werd geïncludeerd voor het onderzoek 
was 1,6 in de intensief ondersteunde groep en 1,0 in de controlegroep (P=0,28). De vier 
meest succesvolle apotheken includeerden 39% van alle geïncludeerde patiënten. Het 
effect van het elektronische volgsysteem in dit onderzoek was vergelijkbaar met de 
resultaten uit eerdere effectstudies. Het totaal aantal geïncludeerde patiënten bleef 
ver achter bij onze verwachtingen. Volgens de apothekers in de intensief ondersteunde 
groep was een gebrek aan tijd, zowel in de huisartspraktijk als in de apotheek, het 
belangrijkste knelpunt. Andere knelpunten waren lage verwachtingen van de huisartsen 
m.b.t. de interventie; huisartsen die vergaten om patiënten naar de apotheek te 
verwijzen; angst van huisartsen om de op vertrouwen gebaseerde relatie met de 
patiënt te beschadigen; en een negatieve houding van apothekers en huisartsen ten 
opzichte van de rol van de zorgverzekeraar die dit onderzoek betaalde in het 
stimuleren van postorderfarmacie en transparantie in huisartspraktijken.
De belangrijkste bevindingen uit dit proefschrift worden bediscussieerd in Hoofdstuk 7. 
Kort samengevat zal een projectmap waarin alle stappen van het implementatieproces 
gedetailleerd zijn beschreven, voor een kwart tot de helft van de openbare apotheken 
voldoende zijn om met een eenvoudig of meer complex FPZ-project aan de slag te 
gaan. Een andere groep (tot 30%) zal baat hebben bij intensieve ondersteuning zoals 
wij die hebben geboden. Voor een derde tot de helft van de apotheken zal een andere 
benadering nodig zijn om specifieke FPZ-projecten te gaan uitvoeren. Net zo 
belangrijk, of misschien nog belangrijker: onze intensieve implementatieondersteuning 
is onvoldoende in staat geweest om de processen te beïnvloeden waarbij huisartsen 
betrokken zijn en die essentieel zijn om te zorgen dat meer patiënten betere 
farmaceutische zorg krijgen. In vergelijking met andere implementatie interventies 
resulteerde onze intensieve ondersteuning in relatief grote verbeteringen in de 
uitvoering van activiteiten door apotheken. Deze verbeteringen werden echter niet 
vertaald in betere farmaceutisch zorg aan patiënten. Bovendien werden de 
apotheekactiviteiten in de statinestudies nauwelijks beïnvloed door de intensieve 
ondersteuning. In dit hoofdstuk worden verschillende interpretaties gegeven van deze 
bevindingen. Tenslotte worden de implicaties voor verder onderzoek en voor de 
praktijk genoemd. Toekomstig onderzoek zou zich moeten richten op het effect van: 
multidisciplinaire bijeenkomsten (met o.a. een apotheker) in de eerste lijn met een 
externe gespreks- en discussieleider; andere vergoedingssystemen; het direct 
betrekken van huisartsen bij de ontwikkeling en de evaluatie van
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implementatieprojecten; een nieuwe rol voor specifiek opgeleid apotheekpersoneel; en 
het op basis van theorieën toespitsen van verbeterinterventies op actief opgespoorde 
knelpunten. Daarnaast zouden patiëntervaringen en psychosociale eigenschappen van 
zorgverleners moeten worden gemeten in toekomstig onderzoek. Aanbevelingen voor 
de praktijk zijn onder andere: advies voor organisaties die apotheken willen 
ondersteunen bij het implementeren van FPZ; het opnemen van een apotheker in een 
multidisciplinair eerstelijns team; gedeeltelijk gezamenlijke opleiding voor apothekers 
en (huis)artsen; onderverdelen van apothekers met een primaire belangstelling voor 
het operationele management en de logistiek van de apotheek aan de ene kant en 
apothekers die zich specialiseren in het verlenen van patiëntgerichte en geïntegreerde 
farmaceutische zorg; en een zorgvuldige selectie van de richtlijn of innovatie die 
geïmplementeerd dient te worden in de klinische praktijk. Wij verwachten dat de 
implementatie van effectieve farmaceutische diensten aanzienlijk beter zal lopen 
indien rekening gehouden wordt met deze voorwaarden.
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Het geeft een bijzonder goed gevoel om terug te blikken op de tot standkoming van dit 
proefschrift, nu het af is! Wat begon met weinig meer dan een idee over wat er 
geïmplementeerd moest worden, groeide uit tot drie complete trials. Het is zonneklaar 
dat heel veel mensen mij hebben ondersteund bij dit proces. Hieronder neem ik graag 
de ruimte om al deze mensen te bedanken.
Allereerst natuurlijk mijn promotoren, professor Peter de Smet en professor Michel 
Wensing. Beste Peter, als één van de geestelijk vaders van dit traject heb je me de 
kans gegeven om onderzoek te doen naar een onderwerp dat me na aan het hart ligt. 
Met je grote strategische inzicht, diplomatie en creativiteit wist je de trein op cruciale 
momenten soepel langs de juiste wissels te loodsen. Op momenten dat het spoor dood 
leek te lopen, vond jij een andere invalshoek met beter perspectief. Ook voor het 
vinden van de juiste formulering voor een lastige boodschap was ik bij jou aan het 
goede adres. Enorm bedankt voor je onmisbare betrokkenheid! Beste Michel, als geen 
ander ben jij in staat om steeds weer uit te gaan van beschikbare feiten, zonder je te 
laten leiden door persoonlijke voorkeuren of belangen. Jouw schematische weergave 
van allerlei processen waren vaak erg verhelderend. De uiteenzettingen over 
verschillende benaderingswijzen door mensen met een verschillende achtergrond 
hebben mij gestimuleerd om een eigen interpretatie te geven van onze bevindingen. 
Tijdens de laatste zware loodjes heb je me enorm geholpen met je pragmatische 
insteek en je nadruk op een heldere structuur. Hartelijk dank voor de waardevolle 
aanvulling van mijn gereedschapskist!
Uit naam van ‘CZ Actief in Gezondheid’ zijn Paul Muijrers, René Bekhuis, Léon van den 
Broeck en Rens van Oosterhout bij dit onderzoek betrokken geweest. Paul, jouw eigen 
proefschrift had al een fundament gelegd voor dit onderzoek. Zonder jouw positieve 
visie op de rol van de apotheker in de eerste lijn was het waarschijnlijk nooit op deze 
manier neergezet. Bedankt daarvoor. Léon, bedankt voor de gezellige ritjes tussen 
stations en lokaties van regionale apothekersbijeenkomsten en voor je blijmoedige 
tegenwicht voor de niet altijd gemakkelijke klus van het werven van deelnemers. René 
en Rens, ook dank voor jullie betrokkenheid, zij het meer op afstand.
Beste Marjan, waar zou ik zijn geweest zonder jouw fantastische ondersteuning?! Vanaf 
de start van de eerste trial heb jij mij bergen werk uit handen genomen. Van het 
maken van projectmappen tot het bellen met apothekers, van het vormgeven van 
vragenlijsten tot het invoeren van data, door jouw inzet heb ik me er geen moment 
zorgen over hoeven maken. Maar misschien nog wel belangrijker voor mij: onze 
samenwerking zich heeft ontwikkeld tot een goede vriendschap. Het gelukkige toeval 
dat we bijna tegelijk onze eerste kindjes kregen heeft daar zeker aan bijgedragen. Ook 
onze tweede kindjes komen nu bijna tegelijk, als we dit boekje tenminste als mijn
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tweede beschouwen. Ik ben heel erg blij en dankbaar dat je bij deze bevalling mijn 
paranimf wilt zijn!
Bij de voorbereiding van de verschillende studies ben ik door veel mensen praktisch 
bijgestaan of van de nodige informatie voorzien. Wim Gorgels, bedankt voor de ins en 
outs over de benzodiazepine stopbrief. Geeske ten Wolde, Waling Tiersma en Geert 
Schattenberg, jullie hebben onder grote tijdsdruk meegewerkt aan het realiseren van 
de vragenlijsten voor geïndividualiseerde benzodiazepine stopbrieven. Erg jammer dat 
het plan om de standaard stopbrief te vergelijken met de brief op maat niet werd 
goedgekeurd door de medisch-ethische commissie, waardoor jullie harde werk 
uiteindelijk voor niets was.
Jozé Braspenning, Jan Mulder, Henk van den Hoogen en Martina Teichert, dank voor het 
meedenken over de precieze onderzoeksvragen, de te verzamelen gegevens uit LINH en 
de interpretatie daarvan. Jozé, jouw nuchtere en pragmatische blik als co-auteur heeft 
erg geholpen om de context van de data mee te nemen in de interpretatie van de 
resultaten. Jan van Lieshout, jij hebt me door het traject heen regelmatig een blik 
gegund door jouw huisartsen- en NHG-bril, waarvoor dank. Carel Bakx, bedankt voor de 
toelichting bij de ICPC-codes en Jako Burgers, hartelijk dank voor je toelichting op de 
discussiepunten voor een herziening van de CBO-richtlijn cardiovasculair 
risicomanagement.
Marvin Tjioe, Bart van der Arend en Karin van Elburg, bedankt dat jullie me goed op 
weg hebben geholpen met de verkennende analyses voor het vinden van de beste 
patiëntgroep voor de statinetrial. Pierre Plouvier en Theo Peters van EuroNed, Gery 
van der Hulst van Microbais en Paul Ubaghs van PharmaPartners, dankzij jullie konden 
alle apothekers aan de slag met patiëntselecties in hun eigen computersysteem. Frank 
Moerkens, het was erg prettig dat ik de selecties in jouw apotheek mocht uitproberen. 
Jannie de Groot, ik was blij dat jij je afstudeerstage kon gebruiken voor het maken van 
de protocollen voor eerste en tweede uitgiftebegeleiding van statines. Gudy Meijvis, 
dank je wel voor het kijkje in jullie keuken! Jan Hermsen, bedankt voor je diensten als 
tweede vertaler van de BMQ, ook al is die in dit proefschrift niet terug te vinden.
Rob Heerdink en Boris van Wijk wil ik bedanken voor het delen van hun ervaringen met 
MEMS-potjesonderzoek. Bastien Renirie en Hans Peter Jung, het was heel fijn dat ik de 
MEMS-interventie bij jullie mocht uittesten. Barbara Wittwer en Raphaël Naoux, thank 
you very much for your excellent support concerning the MEMS caps!
Ook bij de uitvoering van de trials zijn veel mensen betrokken geweest. Peter Felen en 
Luciënne Toonen, jullie trainingsdag was de eerste stap in de intensieve begeleiding 
van apothekers in het benzodiazepineproject. Jullie hebben een mooie mix gemaakt 
van jullie eigen expertise en de specifieke behoeften voor het onderzoek. Graag wil ik 
jullie bedanken voor de training en voor de soepele samenwerking. Angèle van de Ven,
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ik ben blij dat jij tijdens het benzodiazepineproject in beeld kwam om apothekers 
telefonisch te ondersteunen. Met jouw doortastende vragen heb je een aantal 
apothekers stevig over de streep getrokken. Met je kritische blik en je ruime ervaring 
in het ondersteunen van apothekers en huisartsen heb je bovendien een belangrijke rol 
gespeeld in het vormgeven van de intensieve begeleiding van apothekers in de latere 
projecten. Veel dank voor jouw substantiële aandeel in de trials! Daarnaast heb je ons 
in contact gebracht met Annemarie Ruward. Annemarie, ik vergeet nooit meer de 
trainingen waarin je apothekers en projectassistentes soms met een Brigitte Kaandorp­
achtige humor wist aan te spreken. Verder heb ik veel over jouw aanpak geleerd van de 
nabesprekingen na afloop van de trainingen. Hartelijk dank voor de plezierige en 
leerzame samenwerking!
Henriëtte, het was heel goed dat jij ons team vanaf de tweede trial bent komen 
versterken. Jouw bijdragen aan de trainingsbijeenkomsten, het bellen met apothekers, 
het geven van instructie aan apothekers en huisartsen over MEMS-potjes en bloeddruk 
meten en je input voor de nieuwsbrieven waren heel welkom.
Mariëlle Blacha en Thijn Franssen, het was voor mij erg leuk en leerzaam om jullie te 
begeleiden bij jullie wetenschappelijke stage. Als spontane studenten hebben jullie 
waarschijnlijk meer informatie van de huisartsen weten te krijgen dan mij als 
apotheker ooit gelukt was. Mocht ik nog komen tot het schrijven van een artikel over 
deze kwalitatieve data, dan weet ik jullie te vinden.
En dan de dataverwerking. Sandra, Saskia en Geertje, bedankt voor jullie 
ondersteuning bij het opzetten en deels vullen van de databestanden, al was het voor 
ieder van jullie maar kort. Reinier, bedankt voor het uitvoeren van de randomisaties, 
de multilevel analyses en de berekening van ICC’s. Daarnaast was ik erg blij dat je me 
hielp om de juiste vragen te stellen voordat ik aan mijn analyses begon en dat je me 
wegwijs wilde maken in de output van SAS. Ook alle andere onderzoeksmedewerkers 
die paraat stonden bij allerlei SPSS-vragen, wil ik hartelijk bedanken voor de 
laagdrempelige hulp. Fabiënne Griens en Robert Reinder Nederhoed, hartelijk dank 
voor jullie inspanningen om de benzodiazepinesearch aan te passen aan onze wensen 
en om de enorm grote SFK-databestanden, ook voor de tweede trial, goed aan te 
leveren. Voor de voorbewerking en verstrekking van de LINH-data wil ik Christel van 
Dijk en Robert Verheij van het NIVEL van harte bedanken.
Uiteraard had het onderzoek niet eens plaats kunnen vinden als we geen deelnemers 
hadden gehad. Beste apothekers, huisartsen, apothekersassistenten, doktersassistenten 
en praktijkondersteuners, we hebben ons best gedaan om jullie te ondersteunen bij het 
implementeren van de verschillende projecten. Maar het is duidelijk dat jullie het 
uiteindelijk moesten doen. Naast het uitvoeren van alle geplande projecttaken, was 
het ook nog eens nodig om data over het onderzoek te verzamelen. Hartelijk dank dus
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voor alle extra inspanningen die nodig waren voor het invullen van vragenlijsten en 
registratieformulieren en voor het aanleveren van digitale bestanden!
Dat ik het tijdens dit onderzoek zo goed naar mijn zin heb gehad, is voor een belangrijk 
deel te danken aan alle fijne collega’s. Wilma Denneboom, ik was heel blij dat je me 
wegwijs wilde maken tijdens mijn eerste tijd op de afdeling. Ook later (en nu opnieuw) 
heb ik dankbaar gebruik gemaakt van jouw eerdere congres-, poster, en promotie- 
ervaringen. Geert en Karin, de verhuizing naar de kelder was uiteindelijk toch niet zo 
erg omdat jullie fantastische kamergenoten waren met wie ik lief en leed kon delen. 
Aan de vele andere WOK-KWAZO-IQ kamer-, kelder-, gang- en lunchgenoten: hartelijk 
bedankt voor de mooie tijd die ik nu toch echt ga afsluiten. Zeker jullie belangstelling 
bij mijn rechallenge nadat de laatste loodjes me waren opgebroken heb ik ervaren als 
een warm bad. Heel hartelijk bedankt allemaal voor de prettige omgeving die jullie 
voor mij hebben gevormd! Door de jaren heen heb ik bovendien dankbaar gebruik 
gemaakt van de ondersteuning van Anita, Alice, de andere secretaresses, Anja en 
Angelo. Jolanda, ik ben je erg dankbaar dat jij de lay-out en de noodzakelijke 
procedures bij het aanvragen van de promotie voor je rekening hebt genomen!
Rest mij nog om het thuisfront de waardering te geven die het verdient. Janneke, als 
bijzonder goede vriendin heb je me met een luisterend oor en objectieve kijk op de 
zaak een belangrijke steun in de rug gegeven. Ik ben heel erg blij dat je ook bij mijn 
promotie als paranimf achter mij staat! Lieve ouders en schoonouders, jullie hebben 
mijn vorderingen, pieken en dalen van dichtbij kunnen volgen. Het was heel belangrijk 
voor me dat jullie er altijd voor me waren om stoom af te blazen of om mijlpalen te 
vieren. Ook al jullie hulp om het thuis allemaal op rolletjes te laten lopen is van 
onschatbare waarde geweest! Mijn lieve kleine Thomas, je hebt ongetwijfeld het een 
en ander meegekregen van de pittige tijd die aan het tot stand komen van dit 
proefschrift vooraf ging. Maar nu het af is, kunnen we samen nog meer genieten van 
alles waar je vrolijk van wordt. Lieve, lieve Bas. Hoe belangrijk jij voor mij bent, kan ik 
niet goed in woorden uitdrukken. Daarom houd ik het kort: enorm bedankt voor jouw 
onvoorwaardelijke steun, begrip en vertrouwen!
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